



#9
8/9/00
C. Styles

UNITED STATES PATENT AND TRADEMARK OFFICE

I, Andrew Harvey David SUMPTER BSc,

translator to RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.
2. That I am well acquainted with the German and English languages.
3. That the attached is, to the best of my knowledge and belief, a true translation into the English language of the accompanying copy of the specification filed with the application for a patent in Switzerland on 1 November 1995 under the number 03094/95 and the official certificate attached hereto.
4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.

A handwritten signature in black ink, appearing to read "AHD".

For and on behalf of RWS Group plc
The 14th day of June 2000



[Shield]

SWISS CONFEDERATION

Certificate

The attached documents agree with the original technical documents of the Patent Application for Switzerland and Liechtenstein characterised on the next page. Switzerland and the Duchy of Liechtenstein constitute a single territory of protection. Hence, protection can only be requested for both countries conjointly.

Berne, - 9. Sep. 1996

Federal Office for Intellectual Property

Patent applications

U. Kuhler

[Gummed Seal of
Federal Office for
Intellectual Property.]



Patent Application No. 03094/95

Title:

Purine derivatives and processes for their preparation.

Applicant:

CIBA-GEIGY AG Patentabteilung

4002 Basel

Date of filing: 01.11.1995

Prospective classes: A61K, C07D


National Patent Applications Service

Carlo Ferrari

Purine derivatives and processes for their preparation

The invention relates to 2-amino-6-anilino-purine derivatives and to processes and novel intermediates for their preparation, pharmaceutical formulations which comprise such derivatives, and the use of these derivatives as medicaments.

The invention relates to 2-amino-6-anilino-purine derivatives of the formula I



in which q is 1-5,

R₁ is halogen, lower alkyl, hydroxyl or lower alkanoyloxy; lower alkoxy which is unsubstituted or substituted by hydroxyl, lower alkoxy or carboxyl; a radical of the formula -O(-CH₂-CH₂-O)_t-R₆, in which t is 2-5 and R₆ is hydrogen or lower alkyl; carboxyl, lower alkoxycarbonyl, piperazin-1-yl-carbonyl or carbamoyl; N-lower alkyl-carbamoyl which is unsubstituted in the lower alkyl moiety or substituted by hydroxyl or amino; N,N-di-lower alkyl-carbamoyl, cyano, nitro, amino, lower alkanoylamino, lower alkylamino, N,N-di-lower alkylamino, aminosulfonyl or trifluoromethyl, where, if more than one radical R is present in the molecule, these can be identical to or different from one another,

R₂ is hydrogen, carbamoyl or N-lower alkyl-carbamoyl,



m and n are each 0 or 1, where m is 0 if n is 1 and m is 1 if n is 0,

R₃ is lower alkyl or phenyl which are unsubstituted or in each case substituted by hydroxyl, lower alkoxy, amino, lower alkylamino or N,N-di-lower alkylamino, and

a) R₄ is hydrogen, amino, phenylamino, lower alkylamino, hydroxyl, phenoxy, lower alkoxy, acyl having 1-30 C atoms, a substituted aliphatic hydrocarbon radical having not more than

29 C atoms, a carbocyclic radical having not more than 29 C atoms or a heterocyclic radical having not more than 20 C atoms and not more than 9 heteroatoms and R₅ is amino, phenylamino, lower alkylamino, hydroxyl, phenoxy, lower alkoxy, acyl having 2-30 C atoms, a substituted aliphatic hydrocarbon radical having not more than 29 C atoms, a carbocyclic radical having not more than 29 C atoms or a heterocyclic radical having not more than 20 C atoms and not more than 9 heteroatoms, or b) R₄ and R₅ together are a substituted or unsubstituted alkylene or -alkenylene [sic] radical having in each case not more than 15 C atoms, in which 1-3 C atoms can be replaced by oxygen, sulfur or nitrogen, and their salts.

Formula I encompasses the formulae Ia and Ib derived from the corresponding tautomeric purine derivatives, in which the symbols are as defined above.



Unless stated otherwise, in the present disclosure organic radicals designated "lower" contain not more than 7, preferably not more than 4, carbon atoms.

q is preferably 1-3. Only if it is possible for steric reasons, can q also be 4 or 5, for example if R₁ is fluorine.

Acyl R₄ or R₅ having 1-30 C atoms is derived from an unmodified or functionally modified carboxylic acid and is, in particular, one of the part formula Z-C(=W)-, in which W is oxygen, sulfur or imino and Z is hydrogen, hydrocarbyl R° having not more than 29 C atoms, hydrocarbyloxy R°-O- or an amino group, in particular one of the formula R₇(R₈)N-.

Hydrocarbyl (a hydrocarbon radical) R° is an acyclic (aliphatic), carbocyclic or carbocyclic - acyclic hydrocarbon radical having not more than 29 C atoms, in particular not more than 18, and preferably not more than 12, carbon atoms, and is saturated or unsaturated and unsubstituted or substituted. Instead of one, two or more carbon atoms, it can also contain identical or different heteroatoms, such as, in particular, oxygen, sulfur and nitrogen, in the acyclic and/or cyclic moiety; in the latter case, it is called a heterocyclic radical (heterocyclyl radical) or a heterocyclic-acyclic radical.

Unsaturated radicals are those which contain one or more, in particular conjugated and/or isolated, multiple bonds (double bonds and/or triple bonds). The term cyclic radicals also encompasses aromatic radicals, for example those in which at least one 6-membered carbocyclic or one 5- to 8-membered heterocyclic ring contains the maximum number of non-cumulative double bonds. Carbocyclic radicals in which at least one ring is present as a 6-membered aromatic ring (i.e. benzene ring) are called aryl radicals.

An acyclic unsubstituted hydrocarbon radical is, in particular, a straight-chain or branched lower alkyl, lower alkenyl, lower alkadienyl or lower alkynyl radical. Lower alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and furthermore also n-pentyl, isopentyl, n-hexyl, isohexyl and n-heptyl. Lower alkenyl is, for example, allyl, propenyl, isopropenyl, 2- or 3-methallyl and 2- or 3-butenyl. Lower alkadienyl is, for example, 1-penta-2,4-dienyl; lower alkynyl is, for example, propargyl or butynyl. In corresponding unsaturated radicals, the double bond is located, in particular, in a position higher than the α position to the free valency.

A carbocyclic hydrocarbon radical is, in particular, a mono-, bi- or polycyclic cycloalkyl, cycloalkenyl or cycloalkadienyl radical, or a corresponding aryl radical. Preferred radicals are those having not more than 14, in particular 12, ring carbon atoms and 3- to 8-, preferably 5- to 7-, especially 6-membered rings, it also being possible for them to carry one or more, for example two, acyclic radicals, for example those mentioned above, and in particular the lower alkyl radicals, or further carbocyclic radicals. Carbocyclic-acyclic radicals are those in which an acyclic radical, in particular one having not more than 7, preferably not more than 4, carbon atoms, such as, in particular, methyl, ethyl and vinyl, carries one or more carbocyclic radicals, which may or may not be aromatic, as defined above. Cycloalkyl-lower alkyl and aryl-lower alkyl radicals, and their analogues unsaturated in the ring and/or chain, which carry the ring on the terminal C atom of the chain are mentioned in particular.

Cycloalkyl contains, in particular, 3 not more than and including 10 C atoms and is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, as well as bicyclo[2.2.2]octyl, 2-bicyclo[2.2.1]heptyl and adamantyl, which can also be substituted by 1, 2 or more, for example, lower alkyl radicals, in particular methyl radicals; cycloalkenyl is, for example, one of the monocyclic cycloalkyl radicals already mentioned which carries a double bond in the 1, 2 or 3 position. Cycloalkyl-lower alkyl or -lower alkenyl is, for example, a methyl, 1- or 2-ethyl, 1- or 2-vinyl, 1-, 2- or 3-propyl or allyl which is substituted by one of the abovementioned cycloalkyl radicals, those substituted at the end of the linear chain being preferred.

An aryl radical is, in particular, a phenyl, or furthermore a naphthyl, such as 1- or 2-naphthyl, a biphenylyl, such as, in particular, 4-biphenylyl, and moreover also an anthryl, fluorenlyl and azulenyl, as well as their aromatic analogues having one or more saturated rings. Preferred aryl-lower alkyl and -lower alkenyl radicals are, for example, phenyl-lower alkyl or phenyl-lower alkenyl with a terminal phenyl radical, for example benzyl, phenethyl, 1-, 2- or 3-phenylpropyl, diphenylmethyl (benzhydryl), trityl and cinnamyl, and furthermore also 1- or 2-naphthylmethyl. Aryl radicals which carry acyclic radicals, such as lower alkyl, are, in particular, *o*-, *m*- and *p*-tolyl and xylyl radicals with methyl radicals in various sites.

Heterocyclic radicals, including heterocyclic-acyclic radicals, are, in particular, monocyclic, but also bi- or polycyclic, aza-, thia-, oxa-, thiaza-, oxaza-, diaza-, triaza- or tetracyclic radicals of aromatic character, and corresponding partly or, in particular, completely

saturated heterocyclic radicals of this type, it being possible for such radicals to carry, where appropriate, for example as the abovementioned carbocyclic or aryl radicals, further acyclic, carbocyclic or heterocyclic radicals and/or to be mono-, di- or polysubstituted by functional groups. The acyclic moiety in heterocyclic-acyclic radicals is as defined, for example, for the corresponding carbocyclic-acyclic radicals. These are, in particular, unsubstituted or substituted monocyclic radicals with one nitrogen, oxygen or sulfur atom, such as 2-aziridinyl, and in particular aromatic radicals of this type, such as pyrryl, for example 2-pyrryl or 3-pyrryl, pyridyl, for example 2-, 3- or 4-pyridyl, and furthermore thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl; analogous bicyclic radicals with one nitrogen, oxygen or sulfur atom are, for example, indolyl, such as 2- or 3-indolyl, quinolyl, such as 2- or 4-quinolyl, isoquinolyl, such as 3- or 5-isoquinolyl, benzofuranyl, such as 2-benzofuranyl, chromenyl, such as 3-chromenyl, or benzothienyl, such as 2- or 3-benzothienyl; preferred monocyclic and bicyclic radicals with more than one heteroatom are, for example, imidazolyl, such as 2-imidazolyl, pyrimidinyl, such as 2- or 4-pyrimidinyl, oxazolyl, such as 2-oxazolyl, isoxazolyl, such as 3-isoxazolyl, or thiazolyl, such as 2-thiazolyl, or benzimidazolyl, such as 2-benzimidazolyl, benzoxazolyl, such as 2-benzoxazolyl, or quinazolyl, such as 2-quinazolinyl. Corresponding partly, or, in particular, completely saturated analogous radicals are also suitable, such as 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 3-pyrrolidyl, 2-, 3- or 4-piperidyl and also 2- or 3-morpholiny, 2- or 3-thiomorpholiny, 2-piperazinyl and N,N'-bis-lower alkyl-2-piperazinyl radicals. These radicals can also carry one or more acyclic, carbocyclic or heterocyclic radicals, in particular those mentioned above. Heterocyclic-acyclic radicals are derived, in particular, from acyclic radicals having not more than 7, preferably not more than 4, carbon atoms, for example from those mentioned above, and can carry one, two or more heterocyclic radicals, for example those mentioned above, it also being possible for the ring to be bonded to the chain by one of its nitrogen atoms.

As has already been mentioned, a hydrocarbyl (including a heterocyclyl) can be substituted by one, two or more identical or different substituents (functional groups); the following substituents are particularly suitable: free, etherified and esterified hydroxyl groups; mercapto and lower alkylthio and unsubstituted or substituted phenylthio groups; halogen atoms, such as chlorine and fluorine, but also bromine and iodine; oxo groups, which are in the form of formyl (i.e. aldehydo) and keto groups, and also corresponding acetals or ketals; azido and nitro groups; primary, secondary and preferably tertiary amino groups, primary or secondary amino groups protected by conventional protective groups, acylamino groups and

diacylamino groups, and unmodified or functionally modified sulfo groups, such as sulfamoyl groups or sulfo groups present in salt form. All these functional groups should not be on the C atom from which the free valency comes, and they are preferably separated from this by 2 or even more C atoms. The hydrocarbyl radical can also carry free and functionally modified carboxyl groups, such as carboxyl groups present in salt form or esterified carboxyl groups, carbamoyl, ureido or guanidino groups which may or may not carry one or two hydrocarbon radicals, and cyano groups.

An etherified hydroxyl group present as a substituent in hydrocarbyl is, for example, a lower alkoxy group, such as the methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy group, which can also be substituted. Thus, such a lower alkoxy group can be substituted by halogen atoms, for example once, twice or several times, in particular in the 2 position, as in the 2,2,2-trichloroethoxy-, 2-chloroethoxy or 2-iodoethoxy radical, or by hydroxyl or lower alkoxy radicals, in each case preferably once, in particular in the 2-position, as in the 2-methoxyethoxy radical. A particularly preferred embodiment of the etherified hydroxyl groups exists in oxaalkyl radicals in which one or more C atoms in an alkyl, preferably a linear alkyl, are replaced by oxygen atoms, which are preferably separated from one another by more than one (in particular 2) C atoms, so that they form a group $(-\text{O}-\text{CH}_2-\text{CH}_2)_n-$, which may or may not recur more than one, in which n is 1 to 14. Such etherified hydroxyl groups are furthermore also substituted or unsubstituted phenoxy radicals and phenyl-lower alkoxy radicals, such as, in particular, benzyloxy, benzhydryloxy and triphenylmethoxy (trityloxy), as well as heterocyclyloxy radicals, such as, in particular, 2-tetrahydropyranloxy. A particular etherified hydroxyl group is the grouping methylenedioxy or ethylenedioxy, the former as a rule bridging 2 adjacent C atoms, in particular in aryl radicals, and the latter being bonded to one and the same C atom and being regarded as a protective group for oxo.

Etherified hydroxyl groups in this connection are also to be understood as meaning silylated hydroxyl groups, such as are present, for example, in tri-lower alkylsilyloxy, such as trimethylsilyloxy and dimethyl-tert-butylsilyloxy, or phenyl di-lower alkylsilyloxy or lower alkyl-diphenylsilyloxy.

An esterified hydroxyl group present as a substituent in hydrocarbyl is, for example, lower alkanoyloxy.

An esterified carboxyl group present as a substituent in hydrocarbyl is one in which the hydrogen atom is replaced by one of the hydrocarbon radicals characterized above, preferably a lower alkyl or phenyl-lower alkyl radical; an example of an esterified carboxyl group is, for example, lower alkoxy carbonyl or phenyl-lower alkoxy carbonyl which is unsubstituted or substituted in the phenyl moiety, in particular the methoxy-, ethoxy-, tert-butoxy- and benzyloxycarbonyl group, and also a lactonized carboxyl group.

A primary amino group $-NH_2$ as a substituent of hydrocarbyl can also be present in protected form. A secondary amino group carries, instead of one of the two hydrogen atoms, a hydrocarbyl radical, preferably an unsubstituted one, such as one of those mentioned above, in particular lower alkyl, and can also be present in a protected form.

A tertiary amino group occurring as a substituent in hydrocarbyl carries 2 different or, preferably, identical hydrocarbyl radicals (including the heterocyclic radicals) such as the unsubstituted hydrocarbyl radicals characterized above, in particular lower alkyl.

In a group of the formula $R_7(R_8)N-$, R_7 and R_8 independently of one another are each hydrogen, lower alkylsulfonyl, acyclic C_1 - C_7 hydrocarbyl (such as, in particular, C_1 - C_4 alkyl or C_2 - C_4 alkenyl) which is unsubstituted or substituted, for example by amino, guanidino, phenyl, hydroxyphenyl, carboxyl, carbamoyl, imidazolyl, mercapto or methylthio, or monocyclic aryl, aralkyl or aralkenyl which has not more than 10 C atoms and is unsubstituted or substituted by C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen and/or nitro, it being possible for the carbon-containing radicals R_7 and R_8 to be bonded to one another by a carbon-carbon bond or an oxygen atom, a sulfur atom or a nitrogen atom which is unsubstituted or substituted by hydrocarbyl. In such a case, together with the nitrogen atom of the amino group, they form a nitrogen-containing heterocyclic ring. Examples of particularly preferred groups of the formula $R_7(R_8)N-$ are the following: amino, lower alkylamino, such as methylamino, or ω -amino-lower alkylamino, such as 2-amino-ethylamino or 3-amino-propylamino; di-lower alkylamino, such as dimethylamino or diethylamino; pyrrolidino, 2-hydroxymethyl-pyrrolidino, piperidino, 4-(2-amino-ethyl)-piperidino, morpholino or thiomorpholino; piperazino, 4-methyl-piperazino, 4-(2-amino-ethyl)-piperazino, or phenylamino, diphenylamino or dibenzylamino which are unsubstituted or, in particular, substituted in the phenyl moiety, for example by lower alkyl, lower alkoxy, halogen and/or nitro; and among the protected groups, in particular lower alkoxy carbonylamino, such as tert-butoxycarbonylamino, phenyl-lower alkoxy carbonylamino,

such as 4-methoxybenzyloxycarbonylamino, and 9-fluorenyl-methoxycarbonylamino.

Preferred groups of the formula Z-C(=W)- in which Z is a group of the formula R₇(R₈)N- are carbamoyl, N-methyl-carbamoyl, N-(ω -amino-lower alkyl)-carbamoyl, N-(α -amino-acyl)-carbamoyl, N-phenyl-carbamoyl, N-methylsulfonyl-carbamoyl and corresponding radicals in which W is not oxygen but sulfur or imino, such as amidino, N-methyl-amidino [CH₃-NH-C(=NH)-], N-methyl-thiocarbamoyl [CH₃-NH-C(=S)-] or N-(ω -amino-lower alkyl)-thiocarbamoyl.

Unless stated otherwise, aromatic carbocyclic and heterocyclic hydrocarbyl radicals above and below can be substituted once or more than once, for example twice or three times, in particular by C₁-C₄alkyl, C₁-C₄alkoxy, halogen, nitro, trifluoromethyl and furthermore carboxyl, C₁-C₄alkoxycarbonyl, methylenedioxy, and/or cyano. Reduced descriptions of substituents given above and below are to be regarded as preferences.

Preferred compounds of the formula I according to the invention are, for example, those in which hydrocarbyl R° has the following preferred meanings of an acyclic hydrocarbyl: a C₁-C₂₀alkyl, a C₂-C₂₀hydroxyalkyl, the hydroxyl group of which is in any position other than the 1 position, preferably in the 2 position, a cyano-[C₁-C₂₀]-alkyl, the cyano group in which is preferably in the 1 or ω position, or a carboxy-[C₁-C₂₀]-alkyl, the carboxyl group of which is preferably in the 1 or ω position and can be present in the free form or also in salt form, or as a C₁-C₄alkylester (C₁-C₄alkoxycarbonyl) or benzylester (benzyloxycarbonyl), and a C₃-C₂₀alkenyl, the free valency of which is not on the same C atom as the double bond, all the radicals mentioned, excluding those having the C₃-C₅alkyl base structure, containing a linear (unbranched) alkyl chain; and furthermore also a linear (mono-, di- to hexa)-oxoalkyl having 4-20 chain members, in which one or more of the C atoms, from C-3 on, of a linear C₄-C₂₀alkyl is replaced by oxygen atoms, which are separated from one another by at least 2 C atoms and are preferably in positions 3, 6, 9, 12, 15 and 18.

Preferred compounds of the formula I according to the invention are also those in which hydrocarbyl R° has the following preferred meanings of a carbocyclic or heterocyclic and also carbocyclic-acyclic or heterocyclic-acyclic hydrocarbyl: a bicyclic or preferably monocyclic aryl, in particular phenyl, and furthermore naphthyl, which can carry one or more of the following substituents: halogen atoms, in particular fluorine, chlorine and bromine, C₁-C₄alkyl radicals, in particular methyl, C₁-C₄alkoxy groups, in particular methoxy,

methylenedioxy, nitro groups and/or carboxyl groups, which can be free or present in a salt form or as C₁-C₄alkyl esters, in particular methoxycarbonyl or ethoxycarbonyl. Preferably, the aryl radicals carry not more than 2 substituents, in particular those of the same type, or only a single substituent; in particular, they are unsubstituted. Preferred heterocyclic hydrocarbyl (heterocycl) is, for example, that which is analogous to the aryl radicals preferred above and, instead of one or 2 C atoms, contains in each case a heteroatom, in particular nitrogen, such as a pyridyl or quinolyl or quinazolyl, where the free valency is located on a C atom, and can also be substituted accordingly. Preferred carbocyclic-acyclic and heterocyclic-acyclic hydrocarbyl radicals are those in which two or three, but preferably only one, of the cyclic radicals defined above, preferably the unsubstituted radical, is carried by a C₁-C₃alkyl, all preferably being located on one C atom, preferably the terminal C atom; unsubstituted benzyl is most preferred.

Particularly preferred compounds of the formula I are those in which R° is C₁-C₇alkyl, in particular C₁-C₄alkyl, hydroxy-C₂-C₁₈alkyl, in particular hydroxy-C₂-C₁₄alkyl, cyano-C₁-C₇alkyl, in particular cyano-C₁-C₄alkyl, carboxy-C₁-C₇alkyl, in particular carboxy-C₁-C₄alkyl, C₁-C₇-alkoxy-carbonyl-C₁-C₇alkyl, in particular C₁-C₄alkoxy-carbonyl-C₁-C₄alkyl, benzyloxy-carbonyl-C₁-C₇alkyl, in particular benzyloxycarbonyl-C₁-C₄alkyl, C₃-C₇alkenyl, phenyl, naphthyl, pyridyl, quinolyl, or quinazolyl, or phenyl-C₁-C₇alkyl, in particular phenyl-C₁-C₃alkyl, it also being possible for the particular aromatic radicals furthermore to be substituted by C₁-C₇alkyl, in particular C₁-C₄alkyl, C₁-C₇alkoxy, in particular C₁-C₄alkoxy, halogen, nitro, trifluoromethyl or furthermore carboxyl, C₁-C₄alkoxy-carbonyl, methylenedioxy and/or cyano, the hydroxyl group in the correspondingly substituted alkyl radical being located, in particular, in the 2 position and the cyano, carboxyl, alkoxy-carbonyl, benzyloxy-carbonyl or phenyl group in the correspondingly substituted alkyl radical being located, in particular, in the 1 or ω position.

Particularly preferred compounds of the formula I are those in which R° is C₁-C₄alkyl, such as methyl or ethyl, hydroxy-C₂-C₁₄alkyl, such as 2-hydroxy-propyl, -hexyl, -decyl or -tetra-decyl, cyano-C₁-C₄alkyl, such as 2-cyano-ethyl, carboxy-C₁-C₄alkyl, such as carboxymethyl, C₁-C₄alkoxycarbonyl-C₁-C₄alkyl, such as methoxycarbonyl-methyl or -ethyl, C₃-C₇alkenyl, such as allyl, or phenyl, the hydroxyl group in the correspondingly substituted alkyl preferably being located in the 2 position and the cyano, carboxyl or alkoxy-carbonyl group being located, in particular, in the 1 or ω position.

A substituted aliphatic hydrocarbon radical R_4 or R_5 having not more than 29 C atoms is a substituted alkyl or in each case mono- or polyunsaturated alkenyl or alkynyl radical having in each case not more than 29 C atoms, i.e. a substituted C_1 - C_{29} alkyl, C_2 - C_{29} alkenyl or C_2 - C_{29} alkynyl radical. As a rule, these radicals, including their substituents, have not more than 19, in particular not more than 12, and especially not more than 10, C atoms. Suitable substituents are also cyclic radicals, so that R_4 and R_5 in each case can also be carbocyclic-aliphatic radicals or heterocyclic-aliphatic radicals having in each case not more than 29 C atoms. The substituted aliphatic hydrocarbon radical, such as, preferably, ethyl or n-propyl radical, can carry one or more identical or different radicals. Depending on the nature of the substituents, these can be attached via a single or multiple bond or linked in spiro form. Preferred substituents are halogen, such as chlorine, fluorine, bromine or iodine, amino, lower alkylamino, ω -amino-lower alkylamino, lower alkanoylamino, aroylamino, such as, in particular, benzoylamino, hydroxylamino, hydroxylimino, lower alkoxy-amino, aryloxyamino, such as, in particular, phenoxyamino, amino-cyclohexyl-amino-, amino-phenyl-amino-, carbamoyl-amino (ureido, $-\text{NH}-\text{C}(=\text{O})-\text{NH}_2$), (N-lower alkyl-carbamoyl)-amino ($-\text{NH}-\text{C}(=\text{O})-\text{NH}$ -lower alkyl), (N-[ω -amino-lower alkyl]-carbamoyl)-amino ($-\text{NH}-\text{C}(=\text{O})-\text{NH}$ -lower alkyl- NH_2), (N-phenyl-carbamoyl)-amino ($-\text{NH}-\text{C}(=\text{O})-\text{NH}$ -phenyl), thio, lower alkylthio, such as methylthio, thiocarbamoyl ($-\text{C}(=\text{S})-\text{NH}_2$), thioureido ($-\text{NH}-\text{C}(=\text{S})-\text{NH}_2$), N-lower alkyl-thioureido ($-\text{NH}-\text{C}(=\text{S})-\text{NH}$ -lower alkyl), N-phenyl-thioureido ($-\text{NH}-\text{C}(=\text{S})-\text{NH}$ -phenyl), guanidino, N-lower alkyl-guanidino, carboxyl, lower alkoxy carbonyl, aryloxycarbonyl, such as, in particular, phenoxy carbonyl, benzyloxy carbonyl, hydroxylaminocarbonyl, aminoacyl-amino, carbamoyl, amidino ($-\text{C}[\text{=NH}]-\text{NH}_2$), cyano, hydroxyl, lower alkoxy, aryloxy, such as, in particular, phenoxy, aminocarbonyl-oxy ($-\text{O}-\text{C}(=\text{O})-\text{NH}_2$), oxo, aminosulfonyl and lower alkylsulfonyl-amino.

Aminoacyl as part of the abovementioned aminoacyl-amino substituent of an aliphatic hydrocarbon radical R_4 or R_5 is, in particular, the C-terminal radical of an amino acid, such as an α -amino acid, for example one of the naturally occurring α -amino acids, in particular one of the 20 essential α -amino acids which regularly occur in proteins, i.e. glycine, alanine, phenylalanine, proline, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, tyrosine, tryptophan, arginine, histidine, lysine, glutamic acid, glutamine, aspartic acid and asparagine, and in addition phenylglycine. Aminoacyl is preferably amino-lower alkanoyl,

which is unsubstituted or substituted by amino, phenyl, hydroxyphenyl, hydroxyl, mercapto, methylthio, indol-3-yl, carbamoyl, carboxyl, guanidino or imidazolyl.

Preferred substituted aliphatic hydrocarbon radicals R_4 or R_5 without cyclic substituents are, for example, 2-carbamoyl-1-carboxy-eth-1-yl, 3-amino-2-hydroxy-prop-1-yl, 3-amino-prop-1-yl, 3-amino-2,2-dimethyl-prop-1-yl, 3-amino-2-oxo-prop-1-yl, 3-amino-1-carboxy-prop-1-yl, 3-amino-3-carboxy-prop-1-yl, 1,1-dicarbamoyl-methyl, 2-carbamoyl-eth-1-yl, 3-amino-1,3-di-hydroxyimino-prop-1-yl, 2-carbamoyl-1-hydroxyimino-eth-1-yl, 1-hydroxyimino-2-thiocarbamoyl-eth-1-yl, 3-amino-3-hydroxyimino-1-thio-prop-1-yl, 3-amino-pent-1-yl, 1-amino-pent-3-yl, 1-amidino-1-carbamoyl-methyl, 4-amino-1,1,1,3,5,5,5-heptafluoro-pent-2-yl, 3-amino-1,3-dicarboxy-prop-1-yl, 2-carbamoyl-1-ethoxycarbonyl-eth-1-yl, 2-amino-1,2-dithio-eth-1-yl, 2-amino-1,2-dioxo-eth-1-yl, 2-amino-2-methyl-prop-1-yl, 1-amino-2-methyl-prop-2-yl, 2-amino-prop-1-yl, 1-amino-prop-2-yl, 2-amino-eth-1-yl, 2-amino-2-carboxy-eth-1-yl, 2-amino-1-carboxy-eth-1-yl, carbamoyl-methyl, 1-carbamoyl-3-methyl-but-1-yl, 2-amino-1,2-dicarboxy-eth-1-yl, 1-carbamoyl-3-methylthio-prop-1-yl, 1-carbamoyl-2-methyl-prop-1-yl, 1-carbamoyl-eth-1-yl, 1-carbamoyl-1-cyano-methyl, 1-carbamoyl-3-carboxy-3-fluoro-prop-1-yl, 1-carbamoyl-2-carboxy-eth-1-yl, 2-amino-4-carboxy-but-1-yl, 1-amino-4-carboxy-but-2-yl, 1-carbamoyl-4-guanidino-but-1-yl, 1-carbamoyl-5-amino-pent-1-yl, 1-carbamoyl-2-hydroxy-prop-1-yl, 1-carbamoyl-2-methyl-but-1-yl, 1-carbamoyl-2-hydroxy-eth-1-yl, 1,3-dicarbamoyl-prop-1-yl, 2-amino-but-1-yl, 1-amino-but-2-yl, 1-carbamoyl-pent-1-yl and 1-carbamoyl-but-1-yl.

A carbocyclic-aliphatic radical R_4 or R_5 can be substituted both in the carbocyclic and in the aliphatic moiety and is, for example, a cycloaliphatic-aliphatic radical, for example cycloalkyl-lower alkyl or -lower alkenyl, for example a methyl, 1- or 2-ethyl, 1- or 2-vinyl, 1-, 2- or 3-propyl or allyl substituted by one of the cycloalkyl radicals mentioned above or below, those substituted at the end of the linear chain being preferred, or an aromatic-aliphatic radical. Preferred carbocyclic-aliphatic radicals R_4 or R_5 are, for example, benzyl, 2-phenyl-ethyl, 3-aminomethyl-benzyl, (1-hydroxy-cyclohex-1-yl)-methyl, (2-amino-3,5,5-trimethyl-cyclopentyl)-methyl, 1-[N-(1-carboxy-2-phenyl-ethyl)-carbamoyl]-2-carbamoyl-eth-1-yl, 1-carbamoyl-1-phenyl-methyl, 1-carbamoyl-2-(4-hydroxy-phenyl)-eth-1-yl, 1-carbamoyl-2-phenyl-eth-1-yl, 2-amino-1,2-diphenyl-eth-1-yl, 2-benzyloxycarbonyl-1-carbamoyl-eth-1-yl, 3-benzyloxycarbonyl-1-carbamoyl-prop-1-yl, 1-adamantyl-2-amino-prop-1-yl and 1-adamantyl-1-amino-prop-2-yl.

A heterocyclic-aliphatic radical R_4 or R_5 can be substituted both in the heterocyclic and in the aliphatic moiety. Preferred heterocyclic-aliphatic radicals R_4 or R_5 are, for example, (2-furyl)-methyl, (2-tetrahydrofuryl)-methyl, 2-pyrid-2-yl-ethyl, 2-piperidino-ethyl, 2-(morpholin-4-yl)-ethyl, 2-(3-indolyl)-ethyl, 2-(4-imidazolyl)-ethyl, 1-carbamoyl-2-(β -indolyl)-eth-1-yl, 1-carbamoyl-2-imidazol-4-yl-eth-1-yl, 1-carbamoyl-2-indol-3-yl-eth-1-yl, 3-aminomethyl-oxetan-3-yl-methyl and 1-(acetoxy-imino)-1-(4-amino-2-oxa-1,3-diazol-5-yl)-methyl.

A carbocyclic radical R_4 or R_5 having not more than 29 C atoms is such an unsubstituted or substituted hydrocarbon radical, i.e. such a cycloaliphatic or aromatic radical. A carbocyclic hydrocarbon radical is, in particular, a mono-, bi- or polycyclic cycloalkyl, cycloalkenyl or cycloalkadienyl radical, or a corresponding aryl radical. Radicals having not more than 14, in particular 12, ring carbon atoms and 3- to 8-, preferably 5- to 7-, in particular 6-membered rings are preferred, it also being possible for them to carry one or more, for example two, acyclic radicals, for example those mentioned above, and in particular the lower alkyl radicals, or further carbocyclic radicals.

Cycloalkyl represented by the radicals R_4 or R_5 contains, in particular, 3 not more than and including 10 C atoms and is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, as well as bicyclo[2.2.2]octyl, 2-bicyclo[2.2.1]heptyl and adamanyl, which can also be substituted by 1, 2 or more, for example lower, alkyl radicals, in particular methyl radicals; cycloalkenyl is, for example, one of the monocyclic cycloalkyl radicals already mentioned which carries a double bond in the 1, 2 or 3 position.

An aryl radical represented by the radicals R_4 or R_5 is, in particular, a phenyl, furthermore a naphthyl, such as 1- or 2-naphthyl, a biphenylyl, such as, in particular, 4-biphenylyl, and moreover also an anthryl, fluorenyl or azulenyl radical, and their aromatic analogues with one or more saturated rings. Preferred aryl-lower alkyl and -lower alkenyl radicals are, for example, phenyl-lower alkyl or phenyl-lower alkenyl with a terminal phenyl radical, such as, for example, benzyl, phenethyl, 1-, 2- or 3-phenylpropyl, diphenylmethyl (benzhydryl), trityl and cinnamyl, and furthermore also 1- or 2-naphthylmethyl. Aryl radicals which carry acyclic radicals, such as lower alkyl, are, in particular, o-, m- and p-tolyl and xylyl radicals with methyl radicals in various sites.

Preferred carbocyclic radicals R_4 or R_5 are, for example, 2-amino-cyclohex-1-yl, 3-amino-cyclohex-1-yl, 2-aminomethyl-3,3,5-trimethyl-cyclopent-1-yl, 3-amino-adamantan-1-yl, 2-carbamoyl-bicyclo[2.2.1]hept-5-en-3-yl, 2-carbamoyl-cyclohex-1-yl and 9-amino-spiro[4,4]non-1-yl.

Heterocyclic radicals R_4 or R_5 having not more than 20 C atoms and not more than 9 heteroatoms are preferably bonded via one of their ring carbon atoms and are, in particular, monocyclic, but also bi- or polycyclic, aza-, thia-, oxa-, thiaza-, oxaza-, diaza-, triaza- or tetrazacyclic radicals of aromatic character, and corresponding partly or, in particular, completely saturated heterocyclic radicals of this type, it being possible for such radicals, where appropriate, for example like the abovementioned carbocyclic or aryl radicals, to carry further acyclic, carbocyclic or heterocyclic radicals and/or to be mono-, di- or polysubstituted by functional groups. In particular, they are unsubstituted or substituted monocyclic radicals with one nitrogen, oxygen or sulfur atom, such as 2-aziridinyl, and in particular aromatic radicals of this type, such as pyrryl, for example 2-pyrryl or 3-pyrryl, pyridyl, for example 2-, 3- or 4-pyridyl, and furthermore thienyl, for example 2- or 3-thienyl, or furyl, for example 2-furyl; analogous bicyclic radicals with one nitrogen, oxygen or sulfur atom are, for example, indolyl, such as 2- or 3-indolyl, quinolyl, such as 2- or 4-quinolyl, isoquinolyl, such as 3- or 5-isoquinolyl, benzofuranyl, such as 2-benzofuranyl, chromenyl, such as 3-chromenyl, or benzothienyl, such as 2- or 3-benzothienyl; preferred monocyclic and bicyclic radicals with more than one heteroatom are, for example, imidazolyl, such as 2-imidazolyl, pyrimidinyl, such as 2- or 4-pyrimidinyl, oxazolyl, such as 2-oxazolyl, isoxazolyl, such as 3-isoxazolyl, or thiazolyl, such as 2-thiazolyl, or benzimidazolyl, such as 2-benzimidazolyl, benzoxazolyl, such as 2-benzoxazolyl, or quinazolyl, such as 2-quinazolinyl. Also suitable are corresponding partly or, in particular, completely saturated analogous radicals, such as 2-tetrahydrofuryl, 4-tetrahydrofuryl, 2- or 3-pyrrolidyl, 2-, 3-, or 4-piperidyl, and also 2- or 3-morpholinyl, 2- or 3-thiomorpholinyl, 2-piperazinyl and N,N'-bis-lower alkyl-2-piperazinyl radicals. These radicals can also carry one or more acyclic, carbocyclic or heterocyclic radicals, in particular those mentioned above.

A heterocyclic radical R_4 or R_5 can be substituted by one, two or more identical or different substituents (functional groups); the following substituents are particularly suitable: free, etherified and esterified hydroxyl groups; mercapto and lower alkylthio and substituted and

unsubstituted phenylthio groups; halogen atoms, such as chlorine and fluorine, but also bromine and iodine; oxo groups, which are in the form of formyl (i.e. aldehydo) and keto groups, and also corresponding acetals or ketals; azido and nitro groups; primary, secondary and, preferably, tertiary amino groups, primary or secondary amino groups, acylamino groups and diacylamino groups protected by conventional protective groups, and unmodified or functionally modified sulfo groups, such as sulfamoyl groups or sulfo groups present in salt form. All these functional groups should not be on the C atom from which the free valency comes, and they are preferably separated from it by 2 or even more C atoms. The heterocyclic radical can also carry free and functionally modified carboxyl groups, such as carboxyl groups present in salt form or esterified carboxyl groups, carbamoyl, ureido or guanidino groups, which may or may not carry one or two hydrocarbon radicals, and cyano groups.

Preferred heterocyclic radicals R_4 or R_5 are, for example, 5-amino-2-oxa-1,3-diazol-4-yl, 4-amino-thien-3-yl, 3-carbamoyl-5-(3-[2,4-dichloro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 3-carbamoyl-5-(3-[4-trifluoro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 4-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-3-yl, 3-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-4-yl, [1,2,5]oxadiazolo[3,4-b](6-amino-pyrazin-5-yl), 2,5'-diacetyl-3-amino-thieno[2,3-b]thiophen-4'-yl and 3-amino-2,5'-dipivaloyl-thieno[2,3-b]thiophen-4'-yl.

A substituted or unsubstituted alkylene or alkenylene radical having in each case not more than 15 C atoms, in which 1-3 C atoms can be replaced by oxygen, sulfur or nitrogen, which is represented by R_4 and R_5 together, preferably has not more than 10 C atoms.

Substituents are, for example, those mentioned above for substituted aliphatic hydrocarbon radicals R_5 . Preferred radicals are, for example, 1,2-ethylene, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, 3-(3-amino-propionyl)-3-aza-pentane-1,5-diyl, as well as in particular 1-aminomethyl-butane-1,4-diyl, 1-hydroxymethyl-butane-1,4-diyl, 3-(2-amino-ethyl)-pentane-1,5-diyl, 3-aza-pentane-1,5-diyl (-CH₂-CH₂-NH-CH₂-CH₂-) or 3-(2-amino-ethyl)-3-aza-pentane-1,5-diyl (-CH₂-CH₂-N[-CH₂-CH₂-NH₂]-CH₂-CH₂-).

Salts of compounds of formula I are, in particular, acid addition salts with organic or inorganic acids, in particular the pharmaceutically acceptable, non-toxic salts. Suitable inorganic acids are, for example, carbonic acid (preferably in the form of carbonates or bicarbonates); hydrohalic acids, such as hydrochloric acid; sulfuric acid; or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfonamic acids,

for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, 2-hydroxybutyric acid, gluconic acid, glucose monocarboxylic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, glucaric acid, galactaric acid; amino acids, such as glutamic acid, aspartic acid, N-methylglycine, acetylaminooacetic acid, N-acetylasparagine or N-acetyl-cysteine, pyruvic acid, acetoacetic acid, phosphoserine, 2- or 3-glycerophosphoric acid, glucose-6-phosphoric acid, glucose-1-phosphoric acid, fructose-1,6-bisphosphoric acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 1- or 3-hydroxynaphthyl-2-carboxylic acid, 3,4,5-trimethoxybenzoic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, nicotinic acid, isonicotinic acid, glucuronic acid, galacturonic acid, methane- or ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalenedisulfonic acid, 2-, 3- or 4-methylbenzene-sulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexyl-sulfamic acid, N-methyl-, N-ethyl- or N-propylsulfamic acid, or other organic protonic acids, such as ascorbic acid.

Compounds of the formula I which carry at least one free carboxyl group can form inner salts or metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)-amine, or heterocyclic bases, for example N-ethyl-piperidine or N,N'-dimethyl-piperazine.

Pharmaceutically unsuitable salts, for example picrates or perchlorates, can also be used for isolation or purification. Only the non-toxic salts which are pharmaceutically acceptable (at the appropriate doses) are used therapeutically, and are therefore preferred.

As a result of the close relationship between the novel compounds in free form and in the form of their salts, including also those salts which can be used as intermediates, for example during purification of the novel compounds or for their identification, where appropriate the free compounds above and below are to be understood appropriately and expediently as also meaning the corresponding salts.

The compounds of the formula I have valuable pharmacologically useful properties. In particular, they display specific inhibiting actions which are of pharmacological interest.

The compounds of the formula I and their pharmaceutically acceptable salts inhibit the enzyme p34^{cdc2}/cyclin B^{cdc13} kinase. In addition to other cdc2-related kinases, this kinase controls certain phases during cell division, in particular the transition from the G₁ phase into the S phase, and in particular the transition from the G₂ phase into the M phase.

The cycle of a eukaryotic cell comprises, in chronological sequence, the interphase and the M phase. The interphase is accompanied by an enlargement of the cell. It in turn comprises, in chronological sequence, the G₁ phase, the S phase and the G₂ phase. In the G₁ phase (G = "gap", i.e. interspace), biosynthetic processes proceed in the cell. In the S phase (synthesis phase), the DNA replicates. The cell then enters the G₂ phase, which ends with the start of mitosis.

The M phase in turn comprises, in chronological sequence, division of the cell nucleus (mitosis) and division of the cytoplasm (cytokinesis).

The abovementioned inhibition of the enzyme p34^{cdc2}/cyclin B^{cdc13} kinase can be demonstrated by the following experiment:

Starfish oocytes are induced into the M phase with 10 µM 1-methyl-adenine, frozen in liquid nitrogen and stored at -80°C. The oocytes are homogenized and centrifuged, as described in D. Arion et al., Cell 55, 371-378 (1988) and V. Rialet und L. Meijer, Anticancer Res. 11, 1581-1590 (1991), as required. For purification of the p34^{cdc2}/cyclin B^{cdc13} kinase, the supernatant of the oocytes is introduced onto p9^{CKShs} Sepharose grains produced from recombinant human protein p9^{CKShs}, as described in L. Azzi et al., Eur. J. Biochem. 203, 353-360 (1992). After 30 minutes at 4°C under constant rotation, the grains are washed thoroughly and the active p34^{cdc2}/cyclin B^{cdc13} kinase is eluted with free protein p9^{CKShs} (3 mg/ml). The kinase eluted is tested as described in L. Meijer et al., EMBO J. 8, 2275-2282 (1989) and EMBO J. 10, 1545-1554 (1991), using histone H1 as the substrate. In this test, the compounds of the formula I and their pharmaceutically acceptable salts have an inhibiting concentration IC₅₀ [µmol/litre] of 0.0005 to 4, usually of 0.001 to 3.

On the basis of this finding, it can be expected that the compounds of the formula I and their pharmaceutically acceptable salts can be used for treatment of hyperproliferative diseases, such as tumours and psoriasis.

As can already be expected on the basis of the inhibiting action on the enzyme p34^{cdc2}/cyclin B^{cdc13} kinase described above, the compounds of the formula I and their pharmaceutically acceptable salts have antiproliferative properties which can be demonstrated directly in another test as follows: here, the inhibiting action of the compounds of the formula I on the growth of human T24 bladder carcinoma cells is determined. These cells are incubated in "Eagle's minimal essential medium", to which 5% (v/v) of foetal calf serum is added, in a humidified incubator at 37°C and 5 percent by volume CO₂ in air. The carcinoma cells (1000-1500) are seeded into 96-well microtitre plates and incubated overnight under the abovementioned conditions. The test substance is added in serial dilutions on day 1. The plates are incubated under the abovementioned conditions for 5 days. During this period of time, the control cultures pass through at least 4 cell divisions. After the incubation, the cells are fixed with 3.3% (W/V) aqueous glutaraldehyde solution, washed with water and stained with 0.05% (weight/volume) aqueous methylene blue solution. After washing, the dye is eluted with 3% (W/V) aqueous hydrochloric acid. Thereafter, the optical density (OD) per well, which is directly proportional to the cell count, is measured with a photometer (Titertek multiskan) at 665 nm. The IC₅₀ values are calculated with a computer system using the formula

$$\frac{\text{OD } 665(\text{Test}) \text{ minus OD } 665(\text{Initial})}{\text{OD } 665(\text{Control}) \text{ minus OD } 665(\text{Initial})} \times 100.$$

The IC₅₀ values are defined as that concentration of active compound at which the number of cells per well at the end of the incubation period is only 50% of the cell count in the control cultures. The IC₅₀ values determined in this way are about 0.1 to 30 µmol/litre for the compounds of the formula I and their pharmaceutically acceptable salts.

The antitumoural action of the compounds of the formula I can also be demonstrated in vivo: to determine the antitumoural action, female Balb/c naked mice with subcutaneously transplanted human bladder tumours T24 are used. On day 0, about 25 mg of a solid

tumour is pushed under the skin on the left flank of the animals under peroral Forene anaesthesia and the small incision wound is closed by means of wound clamps. On day 6 after the transplant, the mice are divided randomly into groups of 6 animals and treatment is started. The treatment is carried out for 15 days with a single daily peroral or intraperitoneal administration of a compound of the formula I in dimethyl sulfoxide/Tween 80/sodium chloride solution in the various doses. Twice a week, the tumours are measured with a slide gauge and the tumour volume is calculated. In this test, peroral or intraperitoneal administration of a compound of the formula I or of a pharmaceutically acceptable salt thereof causes a significant reduction in the average tumour volume compared with the untreated control animals.

Preferred compounds of the formula I are those in which

q is 1-5,

R_1 is halogen, lower alkyl, hydroxyl or lower alkanoyloxy; lower alkoxy which is unsubstituted or substituted by hydroxyl, lower alkoxy or carboxyl; a radical of the formula $-O(-CH_2-CH_2-O)_t-R_6$, in which t is 2-5 and R_6 is hydrogen or lower alkyl; carboxyl, lower alkoxy carbonyl, piperazin-1-yl-carbonyl or carbamoyl; N-lower alkyl-carbamoyl, which is unsubstituted or substituted by hydroxyl or amino in the lower alkyl moiety; N,N-di-lower alkyl-carbamoyl, cyano, nitro, amino, lower alkanoylamino, lower alkylamino, N,N-di-lower alkylamino, aminosulfonyl or trifluoromethyl, where, if more than one radical R is present in the molecule, these can be identical to or different from one another,

R_2 is hydrogen, carbamoyl or N-lower alkyl-carbamoyl,

m and n are each 0 or 1, where m is 0 if n is 1 and m is 1 if n is 0,

R_3 is lower alkyl or phenyl which are unsubstituted or in each case substituted by hydroxyl, lower alkoxy, amino, lower alkylamino or N,N-di-lower alkyl amino, and

a) R_4 is hydrogen, amino, phenylamino, lower alkylamino, hydroxyl, phenoxy, lower alkoxy; an acyl radical of the part formula $Z-C(=W)-$, in which W is oxygen, sulfur or imino and Z is hydrogen, hydrocarbyl R° , hydrocarbyloxy $R^\circ-O-$ or an amino group of the formula $R_7(R_8)N-$, in which R° in each case is C_1-C_4 alkyl, hydroxy- C_2-C_{14} alkyl, cyano- C_1-C_4 alkyl, carboxy- C_1-C_4 alkyl, C_1-C_4 alkoxy carbonyl- C_1-C_4 alkyl, C_3-C_7 alkenyl or phenyl and R_7 and R_8 independently of one another are each hydrogen, lower alkyl, ω -amino-lower alkyl, lower alkylsulfonyl or phenyl;

an aliphatic hydrocarbon radical having not more than 29 C atoms, which is substituted by halogen, amino, lower alkylamino, ω -amino-lower alkylamino, lower alkanoylamino,

benzoylamino, hydroxylamino, hydroxylimino, lower alkoxy-amino, phenyloxyamino, amino-cyclohexyl-amino-, amino-phenyl-amino-, carbamoyl-amino, (N-lower alkyl-carbamoyl)-amino, (N-[ω -amino-lower alkyl]-carbamoyl)-amino, (N-phenyl-carbamoyl)-amino, thio, lower alkylthio, thiocarbamoyl, thioureido, N-lower alkyl-thioureido, N-phenyl-thioureido, guanidino, N-lower alkyl-guanidino, carboxyl, lower alkoxycarbonyl, phenyloxycarbonyl, benzyloxycarbonyl, hydroxylaminocarbonyl, carbamoyl, amidino, cyano, hydroxyl, lower alkoxy, phenyl-oxy, aminocarbonyl-oxy, oxo, aminosulfonyl, lower alkylsulfonyl-amino, glycylamino, alanyl-amino, phenylalanyl-amino, proylamino, valylamino, leucylamino, isoleucylamino, seryl-amino, threonylamino, cysteinylamino, methionylamino, tyrosylamino, tryptophanyl-amino, arginylamino, histidylamino, lysylamino, glutamylamino, glutaminylamino, asparagylamino, asparaginylamino or phenylglycylamino;

benzyl, 2-phenyl-ethyl, 3-aminomethyl-benzyl, (1-hydroxy-cyclohex-1-yl)-methyl, (2-amino-3,5,5-trimethyl-cyclopentyl)-methyl, 1-[N-(1-carboxy-2-phenyl-ethyl)-carbamoyl]-2-carbamoyl-eth-1-yl, 1-carbamoyl-1-phenyl-methyl, 1-carbamoyl-2-(4-hydroxy-phenyl)-eth-1-yl, 1-carbamoyl-2-phenyl-eth-1-yl, 2-amino-1,2-diphenyl-eth-1-yl, 2-benzyloxycarbonyl-1-carbamoyl-eth-1-yl, 3-benzyloxycarbonyl-1-carbamoyl-prop-1-yl, 1-adamantyl-2-amino-prop-1-yl, 1-adamantyl-1-amino-prop-2-yl,

(2-furyl)-methyl, (2-tetrahydrofuryl)-methyl, 2-pyrid-2-yl-ethyl, 2-piperidino-ethyl, 2-(morpholin-4-yl)-ethyl, 2-(3-indolyl)-ethyl, 2-(4-imidazolyl)-ethyl, 1-carbamoyl-2-(β -indolyl)-eth-1-yl, 1-carbamoyl-2-imidazol-4-yl-eth-1-yl, 1-carbamoyl-2-indol-3-yl-eth-1-yl, 3-aminomethyl-oxetan-3-yl-methyl, 1-(acetoxy-imino)-1-(4-amino-2-oxa-1,3-diazol-5-yl)-methyl, 2-amino-cyclohex-1-yl, 3-amino-cyclohex-1-yl, 2-aminomethyl-3,3,5-trimethyl-cyclopent-1-yl, 3-amino-adamantan-1-yl, 2-carbamoyl-bicyclo[2.2.1]hept-5-en-3-yl, 2-carbamoyl-cyclohex-1-yl, 9-amino-spiro[4.4]non-1-yl,

5-amino-2-oxa-1,3-diazol-4-yl, 4-amino-thien-3-yl, 3-carbamoyl-5-(3-[2,4-dichloro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 3-carbamoyl-5-(3-[4-trifluoro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 4-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-3-yl, 3-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-4-yl, [1,2,5]oxadiazolo[3,4-b](6-amino-pyrazin-5-yl), 2,5'-diacetyl-3-amino-thieno[2,3-b]thiophen-4'-yl or 3-amino-2,5'-dipivaloyl-thieno[2,3-b]thiophen-4'-yl, and

R₅ independently of R₄ is as defined above for R₄, with the exception of hydrogen, or

b) R₄ and R₅ together are 1,2-ethylene, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, 3-(3-amino-propionyl)-3-aza-pentane-1,5-diyl, 1-aminomethyl-butane-1,4-diyl, 1-hydroxy-

methyl-butane-1,4-diyl, 3-(2-amino-ethyl)-pentane-1,5-diyl, 3-aza-pentane-1,5-diyl or 3-(2-amino-ethyl)-3-aza-pentane-1,5-diyl, and their salts.

Compounds of the formula I which are also preferred are those in which
q is 1-3 and
R₄ is hydrogen,
and their salts.

Compounds of the formula I which are also preferred are those in which
q is 1,

R₁ is chlorine which is in the 3 position,

R₂ is hydrogen,

m is 0 and

n is 1,

R₃ is ethyl and

a) R₄ is hydrogen and

R₅ is amino, phenylamino, lower alkylamino, hydroxyl, phenoxy or lower alkoxy; an acyl radical of the part formula Z-C(=W)-, in which W is oxygen, sulfur or imino and Z is hydrogen, hydrocarbyl R°, hydrocarbyloxy R°-O- or an amino group of the formula R₇(R₈)N-, in which R° in each case is C₁-C₄alkyl, hydroxy-C₂-C₁₄alkyl, cyano-C₁-C₄alkyl, carboxy-C₁-C₄alkyl, C₁-C₄alkoxycarbonyl-C₁-C₄alkyl, C₃-C₇alkenyl or phenyl and R₇ and R₈ independently of one another are each hydrogen, lower alkyl, ω -amino-lower alkyl, lower alkylsulfonyl or phenyl;

2-carbamoyl-1-carboxy-eth-1-yl, 3-amino-2-hydroxy-prop-1-yl, 3-amino-prop-1-yl, 3-amino-2,2-dimethyl-prop-1-yl, 3-amino-2-oxo-prop-1-yl, 3-amino-1-carboxy-prop-1-yl, 3-amino-3-carboxy-prop-1-yl, 1,1-dicarbamoyl-methyl, 2-carbamoyl-eth-1-yl, 3-amino-1,3-di-hydroxylimino-prop-1-yl, 2-carbamoyl-1-hydroxylimino-eth-1-yl, 1-hydroxylimino-2-thiocarbamoyl-eth-1-yl, 3-amino-3-hydroxylimino-1-thio-prop-1-yl, 3-amino-pent-1-yl, 1-amino-pent-3-yl, 1-amidino-1-carbamoyl-methyl, 4-amino-1,1,1,3,5,5,5-heptafluoro-pent-2-yl, 3-amino-1,3-dicarboxy-prop-1-yl, 2-carbamoyl-1-ethoxycarbonyl-eth-1-yl, 2-amino-1,2-dithio-eth-1-yl, 2-amino-1,2-dioxo-eth-1-yl, 2-amino-2-methyl-prop-1-yl, 1-amino-2-methyl-prop-2-yl, 2-amino-prop-1-yl, 1-amino-prop-2-yl, 2-amino-eth-1-yl, 2-amino-2-carboxy-eth-1-yl, 2-amino-1-carboxy-eth-1-yl, carbamoyl-methyl, 1-carbamoyl-3-methyl-but-1-yl, 2-amino-1,2-dicarboxy-eth-1-yl, 1-carbamoyl-3-methylthio-prop-1-yl, 1-carbamoyl-2-methyl-prop-1-yl,

1-carbamoyl-eth-1-yl, 1-carbamoyl-1-cyano-methyl, 1-carbamoyl-3-carboxy-3-fluoro-prop-1-yl, 1-carbamoyl-2-carboxy-eth-1-yl, 2-amino-4-carboxy-but-1-yl, 1-amino-4-carboxy-but-2-yl, 1-carbamoyl-4-guanidino-but-1-yl, 1-carbamoyl-5-amino-pent-1-yl, 1-carbamoyl-2-hydroxy-prop-1-yl, 1-carbamoyl-2-methyl-but-1-yl, 1-carbamoyl-2-hydroxy-eth-1-yl, 1,3-dicarbamoyl-prop-1-yl, 2-amino-but-1-yl, 1-amino-but-2-yl, 1-carbamoyl-pent-1-yl, 1-carbamoyl-but-1-yl; benzyl, 2-phenyl-ethyl, 3-aminomethyl-benzyl, (1-hydroxy-cyclohex-1-yl)-methyl, (2-amino-3,5,5-trimethyl-cyclopentyl)-methyl, 1-[N-(1-carboxy-2-phenyl-ethyl)-carbamoyl]-2-carbamoyl-eth-1-yl, 1-carbamoyl-1-phenyl-methyl, 1-carbamoyl-2-(4-hydroxy-phenyl)-eth-1-yl, 1-carbamoyl-2-phenyl-eth-1-yl, 2-amino-1,2-diphenyl-eth-1-yl, 2-benzyloxycarbonyl-1-carbamoyl-eth-1-yl, 3-benzyloxycarbonyl-1-carbamoyl-prop-1-yl, 1-adamantyl-2-amino-prop-1-yl, 1-adamantyl-1-amino-prop-2-yl,
(2-furyl)-methyl, (2-tetrahydrofuryl)-methyl, 2-pyrid-2-yl-ethyl, 2-piperidino-ethyl, 2-(morpholin-4-yl)-ethyl, 2-(3-indolyl)-ethyl, 2-(4-imidazolyl)-ethyl, 1-carbamoyl-2-(β -indolyl)-eth-1-yl, 1-carbamoyl-2-imidazol-4-yl-eth-1-yl, 1-carbamoyl-2-indol-3-yl-eth-1-yl, 3-aminomethyl-oxetan-3-yl-methyl, 1-(acetoxy-imino)-1-(4-amino-2-oxa-1,3-diazol-5-yl)-methyl, 2-amino-cyclohex-1-yl, 3-amino-cyclohex-1-yl, 2-aminomethyl-3,3,5-trimethyl-cyclopent-1-yl, 3-amino-adamantan-1-yl, 2-carbamoyl-bicyclo[2.2.1]hept-5-en-3-yl, 2-carbamoyl-cyclohex-1-yl, 9-amino-spiro[4.4]non-1-yl,

5-amino-2-oxa-1,3-diazol-4-yl, 4-amino-thien-3-yl, 3-carbamoyl-5-(3-[2,4-dichloro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 3-carbamoyl-5-(3-[4-trifluoro-phenyl]-1-oxo-prop-2-en-1-yl)-1,2-thiazol-4-yl, 4-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-3-yl, 3-amino-2-(4-carboxy-butyl)-tetrahydrothiophen-4-yl, [1,2,5]oxadiazolo[3,4-b](6-amino-pyrazin-5-yl), 2,5'-diacetyl-3-amino-thieno[2,3-b]thiophen-4'-yl or 3-amino-2,5'-dipivaloyl-thieno[2,3-b]thiophen-4'-yl, or

b) R₄ and R₅ together are 1,2-ethylen, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, 3-(3-amino-propionyl)-3-aza-pentane-1,5-diyl, 1-aminomethyl-butane-1,4-diyl, 1-hydroxy-methyl-butane-1,4-diyl, 3-(2-amino-ethyl)-pentane-1,5-diyl, 3-aza-pentane-1,5-diyl or 3-(2-amino-ethyl)-3-aza-pentane-1,5-diyl,

and their salts.

Particularly preferred compounds of the formula I are those in which
q is 1-3,

R_1 is halogen, lower alkyl or lower alkoxy; N-lower alkyl-carbamoyl, which is substituted in the lower alkyl moiety by hydroxyl; or trifluoromethyl, where, if more than one radical R is present in the molecule, these can be identical or different from one another,
 R_2 is hydrogen,

m and n are each 0 or 1, where m is 0 if n is 1 and m is 1 if n is 0,

R_3 is lower alkyl which is unsubstituted or substituted by hydroxyl and

a) R_4 is hydrogen or hydroxy-lower alkyl and

R_5 is 2-amino-cyclohexyl; or lower alkyl which is substituted by amino, lower alkylamino, ω -amino-lower alkylamino, hydroxyl, lower alkoxy, phenyl, 3-aminomethyl-phenyl, 2-furyl, 2-tetrahydrofuryl, 2-pyridyl, piperidino, morpholin-4-yl, 3-indolyl, mercapto, 1-hydroxy-cyclohex-1-yl or by 4-imidazolyl; or


b) R_4 and R_5 together are an alkylene radical having not more than 10 C atoms, which is unsubstituted or substituted by hydroxyl or amino and in which 1 C atom can be replaced by nitrogen,

and their salts.

The compounds of the formula I mentioned in the Examples and their pharmaceutically acceptable salts are most preferred.


The compounds of the formula I and their pharmaceutically acceptable salts are prepared by processes known per se, for example by

a) reacting a compound of the formula II




in which Y is a suitable leaving group and the other substituents and symbols are as defined above for compounds of the formula I, free functional groups present in this compound, if

necessary, being protected by easily detachable protective groups, with an amine of the formula III



in which the substituents are as defined above for compounds of the formula I, free functional groups present in this compound, if necessary, being protected by easily detachable protective groups or, in accordance with the principle of latent functionality, being in a form which can be converted into the functional groups, and detaching the protective groups present and, if necessary, converting functional groups into the final form according to formula I, or

b) reacting a compound of the formula V



in which the substituents and symbols are as defined above for compounds of the formula I, free functional groups present in this compound, if necessary, being protected by easily detachable protective groups, with a compound of the formula VI,



in which Y is a suitable leaving group and

R_3 is as defined above for compounds of the formula I, free functional groups present in R_3 , if necessary, being protected by easily detachable protective groups, and detaching the protective groups present, and, after carrying out process a) or b), if necessary for the preparation of a salt, converting a resulting free compound of the formula I into a salt or, if necessary for preparation of a free

compound, converting a resulting salt of a compound of the formula I into the free compound.

The above processes are described in more detail below:

Process a)

A suitable leaving group Y in a starting material of the formula II is preferably halogen, such as bromine, iodine or, in particular, chlorine.

The end substances of the formula I can contain substituents which can also be used as protective groups in starting substances for the preparation of other end substances of the formula I. Unless otherwise evident from the context, "protective groups" in this text, are therefore only those easily detachable groups which are not a constituent of the particular desired end substance of the formula I.

Protective groups, their introduction and their detachment are described, for example, in "Protective Groups in Organic Chemistry", Plenum Press, London, New York 1973, and in "Methoden der organischen Chemie" [Methods of Organic Chemistry], Houben-Weyl, 4th Edition, Volume 15/1, Georg-Thieme-Verlag, Stuttgart 1974 and in Theodora W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, New York 1981. It is characteristic of protective groups that they can be detached easily, i.e. without undesirable side reactions taking place, for example by solvolysis, reduction, photolysis or also under physiological conditions.

Protection of free functional groups in the starting material of the formula II is as a rule not necessary. If desired, free carboxyl or amino groups in the radical R_1 or free amino groups in the radical R_3 can be protected.

In a starting material of the formula III, if desired, for example, free amino groups, with the exception of the amino group participating in the reaction, or free carboxyl groups, can be present in protective form. Protection of some functional groups, for example a second amino group in the amine of the formula III, for example in the case of ethylenediamine, can be avoided by employing the amine of the formula III in a large excess. Functional groups, such as, in particular, leaving groups, for example halogen or toluenesulfonate, however,

can also be present, in accordance with the principle of latent functionality, in a form which can be converted into one of the functional groups according to formula I. Thus, a protected amino group can first be set free by detaching the amino-protective group and the free amino group can then be converted into toluenesulfonate or halogen via an azide in a manner known per se.

A protected amino group can be, for example, in the form of an easily detachable acylamino, arylmethylamino, etherified mercaptoamino or 2-acyl-lower alk-1-en-yl-amino group.

In a corresponding acylamino group, acyl is, for example, the acyl radical of an organic carboxylic acid having, for example, not more than 18 carbon atoms, in particular an alkanecarboxylic acid which is unsubstituted or substituted, for example by halogen or aryl, or of a benzoic acid which is unsubstituted or substituted, for example by halogen, lower alkoxy or nitro, or of a carbonic acid half-ester. Such acyl groups are, for example, lower alkanoyl, such as formyl, acetyl or propionyl, halo-lower alkanoyl, such as 2-haloacetyl, in particular 2-chloro-, 2-bromo-, 2-iodo-, 2,2,2-trifluoro- or 2,2,2-trichloroacetyl, benzoyl which is unsubstituted or substituted, for example by halogen, lower alkoxy or nitro, for example benzoyl, 4-chlorobenzoyl, 4-methoxybenzoyl or 4-nitrobenzoyl, or lower alkoxy carbonyl which is branched in the 1 position of the lower alkyl radical or suitably substituted in the 1 or 2 position, in particular tert-lower alkoxy carbonyl, for example tert-butyloxycarbonyl, arylmethoxycarbonyl with one or two aryl radicals, which are preferably phenyl which is unsubstituted or mono- or polysubstituted, for example by lower alkyl, in particular tert-lower alkyl, such as tert-butyl, lower alkoxy, such as methoxy, hydroxyl, halogen, for example chlorine, and/or nitro, such as unsubstituted or substituted benzyloxycarbonyl, for example 4-nitro-benzyloxycarbonyl, or unsubstituted or substituted diphenylmethoxycarbonyl, for example benzhydryloxycarbonyl or di-(4-methoxyphenyl)-methoxycarbonyl, aroylmethoxycarbonyl, in which the aroyl group is preferably benzoyl which is unsubstituted or substituted, for example by halogen, such as bromine, for example phenacyloxycarbonyl, 2-halo-lower alkoxy carbonyl, for example 2,2,2-trichloroethoxycarbonyl, 2-bromoethoxycarbonyl or 2-iodoethoxycarbonyl, or 2-(trisubstituted silyl)-ethoxycarbonyl, in which the substituents independently of one another are each an aliphatic, araliphatic, cycloaliphatic or aromatic hydrocarbon radical which has not more than 15 C atoms and is unsubstituted or substituted, for example substituted by lower alkyl, lower alkoxy, aryl, halogen or nitro, such as corresponding unsubstituted or substituted lower alkyl, phenyl-lower alkyl, cycloalkyl or

phenyl, for example 2-tri-lower alkylsilylethoxycarbonyl, such as 2-trimethylsilyl-ethoxycarbonyl or 2-(di-n-butyl-methyl-silyl)-ethoxycarbonyl, or 2-triarylsilylethoxycarbonyl, such as 2-triphenylsilylethoxycarbonyl.

In an arylmethylamino group which is a mono-, di- or, in particular, triaryl methylamino group, the aryl radicals are, in particular, substituted or unsubstituted phenyl radicals. Such groups are, for example, benzyl-, diphenylmethyl- and, in particular, tritylamino.

An etherified mercapto group in an amino group protected with such a radical is, in particular, arylthio or aryl-lower alkylthio, in which aryl is, in particular, phenyl which is unsubstituted or substituted, for example by lower alkyl, such as methyl or tert-butyl, lower alkoxy, such as methoxy, halogen, such as chlorine, and/or nitro. A corresponding amino-protective group is, for example, 4-nitrophenylthio.

In a 2-acyl-lower alk-1-en-1-yl radical which can be used as an amino-protective group, acyl is, for example, the corresponding radical of a lower alkanecarboxylic acid, of a benzoic acid which is unsubstituted or substituted, for example by lower alkyl, such as methyl or tert-butyl, lower alkoxy, such as methoxy, halogen, such as chlorine, and/or nitro, or, in particular, of a carbonic acid half-ester, such as a carbonic acid lower alkyl half-ester. Corresponding protective groups are, in particular, 1-lower alkanoyl-prop-1-en-2-yl, for example 1-acetyl-prop-1-en-2-yl, or 1-lower alkoxy carbonyl-prop-1-en-2-yl, for example 1-ethoxycarbonyl-prop-1-en-2-yl.

Preferred amino-protective groups are acyl radicals of carbonic acid half-esters, in particular tert-butyloxycarbonyl, benzyloxycarbonyl which is unsubstituted or substituted, for example as defined, for example 4-nitro-benzyloxycarbonyl, or diphenylmethoxycarbonyl, or 2-halo-lower alkoxy carbonyl, such as 2,2,2-trichlorethoxycarbonyl, and furthermore trityl or formyl.

Preferred protected carboxyl groups are, for example, tert-butoxycarbonyl, benzyloxycarbonyl or diphenylmethoxycarbonyl which are unsubstituted or substituted, or 2-trimethylsilyl-ethoxycarbonyl.

The reaction between the derivative of the formula II and the amine derivative of the formula III can be carried out in suitable inert solvents. If possible, on the basis of the physical nature

of the amine of the formula III, however, the reaction is preferably carried out without a foreign solvent, and the amine of the formula III is employed in a large excess, for example a hundred times the equivalent amount, both as the reagent and as the solvent. Depending on the nature of the specific reactants, such as, in particular, the precise nature of the leaving group Y and the reactivity of the specific amine of the formula III, the reaction is carried out at between 20 °C and 200 °C, preferably between +50 °C and +180 °C, for example under reflux. If Y is chlorine and the amine of the formula III is an aliphatic amine, such as ethylenediamine, the reaction is preferably carried out at between +80 C [sic] and +150 °C, for example at a bath temperature of +150 C [sic].


The protective groups which are not a constituent of the desired end product of the formula I are detached in a manner known per se, for example by means of solvolysis, in particular hydrolysis, alcoholysis or acidolysis, or by means of reduction, in particular hydrogenolysis or chemical reduction, if necessary in stages or simultaneously.

A protected amino group is set free in a manner known per se and, depending on the nature of the protective groups, in diverse manners, preferably by means of solvolysis or reduction. 2-Halo-lower alkoxy carbonylamino (if appropriate after conversion of a 2-bromo-lower alkoxy carbonylamino group into a 2-iodo-lower alkoxy carbonylamino group), aroylmethoxy carbonylamino or 4-nitrobenzyloxycarbonylamino can be split, for example, by treatment with a suitable chemical reducing agent, such as zinc in the presence of a suitable carboxylic acid, such as aqueous acetic acid. Aroylmethoxy carbonylamino can also be split by treatment with a nucleophilic, preferably salt-forming reagent, such as sodium thiophenolate, and 4-nitro-benzyloxycarbonylamino can also be split by treatment with an alkali metal dithionite, for example sodium dithionite. Substituted or unsubstituted diphenylmethoxy carbonylamino, tert-lower alkoxy carbonylamino or 2-trisubstituted silylethoxy carbonylamino can be split by treatment with a suitable acid, for example formic or trifluoroacetic acid, substituted or unsubstituted benzyloxycarbonylamino can be split, for example, by means of hydrogenolysis, i.e. by treatment with hydrogen in the presence of a suitable hydrogenation catalyst, such as a palladium catalyst, and triarylmethylamino or formylamino can be split, for example, by treatment with an acid, such as a mineral acid, for example hydrochloric acid, or an organic acid, for example formic, acetic or trifluoroacetic acid, if appropriate in the presence of water, and an amino group protected by an organic silyl group can be set free, for example, by means of hydrolysis or alcoholysis. An amino


group protected by 2-haloacetyl, for example 2-chloroacetyl, can be set free by treatment with thiourea in the presence of a base or with a thiolate salt, such as an alkali metal thiolate, of urea and subsequent solvolysis, such as alcoholysis or hydrolysis, of the condensation product formed. An amino group protected by 2-substituted silylethoxycarbonyl can also be converted into the free amino group by treatment with a hydrofluoric acid salt which supplies fluoride anions.

The starting material of the formula II in which Y is chlorine is obtained in two stages as follows:

In the first stage, 2,6-dichloro-purine, which is commercially obtainable (for example from Lancaster, Aldrich or Fluka) and is in the form of a mixture of the tautomeric forms 2,6-dichloro-9*H*-purine and 2,6-dichloro-7*H*-purine, is reacted with an amine of the formula IV



in which q, R₁ and R₂ are as defined above, to give a compound of the formula VII



in which Y is chlorine and the other substituents and symbols are as defined for formula I. This reaction is carried out in an inert organic solvent, such as, in particular, an alkanol, for example pentanol, preferably at a temperature between room temperature and +150 °C, for example at a bath temperature of 100 °C, an excess, for example 3-4 times the equivalent amount, of the amine of the formula IV preferably being employed.

In the second stage, the compound of the formula VII is reacted with a compound of the formula VI analogously to process b) to give a compound of the formula II in which Y is chlorine.

The starting material of the formula II in which Y is another leaving group, i.e. different from chlorine, is obtained in an analogous manner.

Process b)

In a starting material of the formulae V or VI, if desired, for example, free amino groups can be present in protected form.

A suitable leaving group Y in a starting material of the formula VI is preferably halogen, such as chlorine, bromine or, in particular, iodine.

The reaction between the derivatives of the formulae V and VI is carried out in a suitable inert solvent, such as, preferably, dimethylformamide or a mixture of dimethylformamide and water, preferably in a volume ratio of 9:1, and preferably in the presence of potassium carbonate or caesium carbonate, for example twice the molar amount of caesium carbonate, compared with the amount of the compound of the formula V, preferably at a reaction temperature of between 0 °C and 150 °C, for example at room temperature. The derivative of the formula VI is preferably employed in an excess here, for example five times the molar amount.

The starting material of the formula V is obtained from a compound of the formula VII with an amine of the formula III analogously to process a).

General process conditions:

Free compounds of the formula I which are obtainable by the process and have salt-forming properties can be converted into their salts in a manner known per se, for example by treatment with acids or suitable derivatives thereof, for example by addition of the acid in question to the compound of the formula I dissolved in a suitable solvent, for example an ether, such as a cyclic ether, in particular dioxane, and especially tetrahydrofuran.

Compounds of the formula I with acid groups, for example free carboxyl groups, are treated, for example, with a suitable base, for example a hydroxide, carbonate or bicarbonate, for salt formation.

Isomer mixtures obtainable according to the invention can be separated into the individual isomers in a manner known per se, for example racemates can be separated by formation of salts with optically pure salt-forming reagents and preparation of the diastereomer mixture thus obtained, for example by means of fractional crystallization.

The abovementioned reactions can be carried out under reaction conditions known per se, in the absence or, usually, presence of solvents or diluents, preferably those which are inert towards the reagents used and dissolve these, in the absence or presence of catalysts, condensation agents (for example phosphorus pentoxide) or neutralizing agents, for example bases, in particular nitrogen bases, such as triethylamine hydrochloride, depending on the nature of the reaction and/or of the reaction participants, at a reduced, normal or elevated temperature, for example in the temperature range from about -80°C to about 200°C, preferably from about -20°C to about 150°C, for example at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, if appropriate under pressure, and/or in an inert atmosphere, for example under a nitrogen atmosphere.

The reaction conditions stated specifically in each case are preferred.

Solvents and diluents are, for example, water, alcohols, for example lower alkylhydroxides, such as methanol, ethanol, propanol or, in particular, butanol, diols, such as ethylene glycol, triols, such as glycerol, or aryl alcohols, such as phenol, acid amides, for example carboxylic acid amides, such as dimethylformamide, dimethylacetamide or 1,3-dimethyl-3,4,5,6--tetrahydro-2(1H)-pyrimidinone (DMPU), carboxylic acids, in particular formic acid or acetic acid, amides of inorganic acids, such as hexamethylphosphoric acid triamide, ethers, for example cyclic ethers, such as tetrahydrofuran or dioxane, or acyclic ethers, such as diethyl ether or ethylene glycol dimethyl ether; halogenated hydrocarbons, such as halo-lower alkanes, for example methylene chloride or chloroform, ketones, such as acetone, nitriles, such as acetonitrile, acid anhydrides, such as acetic anhydride, esters, such as ethyl acetate, bisalkanesulfines, such as dimethyl sulfoxide, nitrogen-containing heterocyclic compounds, such as pyridine, hydrocarbons, for example lower alkanes, such as heptane, or

aromatics, such as benzene, toluene or xylene(s), or mixtures of these solvents, it being possible for the suitable solvents to be chosen in each case for the abovementioned reactions.

The customary processes are used for working up the compounds of the formula I which can be obtained or their salts, for example solvolysis of excess reagents; recrystallization; chromatography, for example partition, ion or gel chromatography; partition between an inorganic and organic solvent phase; one or several extractions, in particular after acidification or increasing the basicity or the salt content; drying over hygroscopic salts; digestion; filtration; washing; dissolving; evaporation (if necessary in *vacuo* or under a high vacuum); distillation; crystallization, for example of the resulting compounds in the form of an oil or from the mother liquor, it also being possible for the product to be seeded with a crystal of the end product; or a combination of two or more of the working up steps mentioned, which can also be employed repeatedly.

Starting materials and intermediates can be used in the pure form for example after working up, as mentioned last, in partly purified form or else, for example, directly as a crude product.


As a result of the close relationship between the compounds of the formula I in the free form and in the form of salts, the free compounds and their salts above and below are to be understood appropriately and expediently, where appropriate, as also meaning the corresponding salts or free compounds if the compounds contain salt-forming groups.

The compounds, including their salts, can also be obtained in the form of hydrates, or their crystals can include, for example, the solvent used for the crystallization.

Those starting substances which lead to the novel compounds of the formula I described above as particularly valuable are preferably employed in the process of the present invention.


The invention also relates to those embodiment forms of the process in which a compound obtainable as an intermediate at any process stage is used as the starting substance and the missing process steps are carried out, or in which a starting substance is formed under the reaction conditions or is used in the form of a derivative, for example a salt thereof.

The invention also relates to the compounds of the formula II



in which Y is a suitable leaving group and the other substituents and symbols are as defined above for compounds of the formula I, free functional groups therein being protected, if necessary, by easily detachable protective groups,
which can be used as starting material for the preparation of the compounds of the formula I.

The invention also relates to the compounds of the formula V



in which the substituents and symbols are as defined above for compounds of the formula I, free functional groups present therein being protected, if necessary, by easily detachable protective groups,

as starting material for the preparation of the compounds of the formula I.

The present invention also relates to pharmaceutical compositions which comprise one of the compounds of the formula I as active ingredient and can be used, in particular, for treatment of the abovementioned diseases. Particularly preferred compositions are those for

enteral, such as nasal, buccal, rectal or, in particular, oral, as well as for parenteral, such as intravenous, intramuscular or subcutaneous, administration to warm-blooded animals, in particular humans. The compositions comprise the active ingredient by itself or, preferably, together with a pharmaceutically acceptable carrier. The dosage of the active ingredient depends on the disease to be treated and on the species, age, weight and individual state thereof, individual pharmacokinetic circumstances of the disease to be treated and the mode of administration.

The invention also relates to pharmaceutical compositions for use in a method for therapeutic treatment of the human or animal body, a process for the preparation thereof (in particular as compositions for tumour treatment) and a method for treatment of tumour diseases, in particular those mentioned above.

A pharmaceutical composition which is suitable for administration to a warm-blooded animal, in particular humans, suffering from a disease which responds to inhibition of a protein kinase, for example psoriasis or a tumour, and comprises a compound of the formula I or a salt thereof, if salt-forming groups are present, in an amount effective for inhibition of the protein kinase, together with at least one pharmaceutically acceptable carrier.

The pharmaceutical compositions comprise about 1 % to about 95 % of the active ingredient, single-dose forms of administration preferably comprising about 20 % to about 90 % of the active ingredient and administration forms which are not single-dose preferably comprising about 5 % to about 20 % of the active ingredient. Unit dose forms are, for example, coated tablets, tablets, ampoules, vials, suppositories or capsules. Other forms of administration are, for example, ointments, creams, pastes, foams, tinctures, lipsticks, drops, sprays, dispersions and the like.

Examples are capsules containing from about 0.05 g to about 1.0 g of the active ingredient.

The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes.

Preferably, solutions of the active ingredient, and in addition also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions, are used, it being possible for these to be prepared before use, for example in the case of lyophilized compositions which comprise the active substance by itself or together with a carrier, for example mannitol. The pharmaceutical compositions can be sterilized and/or comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizing agents, salts for regulating the osmotic pressure and/or buffers, and they are prepared in a manner known per se, for example by means of conventional dissolving or lyophilizing processes. The solutions or suspensions mentioned can comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.

Suspensions in oil comprise, as the oily component, the vegetable, synthetic or semi-synthetic oils customary for injection purposes. Oils which may be mentioned are, in particular, liquid fatty acid esters which contain, as the acid component, a long-chain fatty acid having 8-22, in particular 12-22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidinic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, euric acid, brasidic acid or linoleic acid, if appropriate with the addition of antioxidants, for example vitamin E, β -carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of these fatty acid esters has not more than 6 carbon atoms and is a mono- or polyhydric, for example mono-, di- or trihydric, alcohol, for example methanol, ethanol, propanol, butanol, or pentanol, or isomers thereof, but in particular glycol and glycerol. Fatty acid esters are therefore, for example: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxyethylene glycerol trioleate from Gattefossé, Paris), "Labrafil M 1944 CS" (unsaturated polyglycolated glycerides prepared by an alcoholysis of apricot kernel oil and made up of glycerides and polyethylene glycol esters; Gattefossé, France), "Labrasol" (saturated polyglycolated glycerides, prepared by alcoholysis of TCM and made up of glycerides and polyethylene glycol esters; Gattefossé, France) and/or "Miglyol 812" (triglyceride of saturated fatty acids of chain length C₈ to C₁₂ from Hüls AG, Germany), and in particular vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and, in particular, groundnut oil.

The preparation of the injection compositions is carried out in the customary manner under sterile conditions, as are bottling, for example in ampoules or vials, and closing of the containers.

For example, pharmaceutical compositions for oral use can be obtained by combining the active ingredient with one or more solid carriers, if appropriate granulating the resulting mixture, and, if desired, processing the mixture or granules to tablets or coated tablet cores, if appropriate by addition of additional excipients.

Suitable carriers are, in particular, fillers, such as sugars, for example lactose, sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate, or calcium hydrogen phosphate, and furthermore binders, such as starches, for example maize, wheat, rice or potato starch, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the abovementioned starches, and furthermore carboxymethyl-starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients are, in particular, flow regulators and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol, or derivatives thereof.

Coated tablet cores can be provided with suitable coatings which, if appropriate, are resistant to gastric juice, the coatings used being, *inter alia*, concentrated sugar solutions, which, if appropriate, comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, coating solutions in suitable organic solvents or solvent mixtures or, for the preparation of coatings which are resistant to gastric juice, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments can be admixed to the tablets or coated tablet coatings, for example for identification or for characterization of different doses of active ingredient.

Pharmaceutical compositions which can be used orally are also hard capsules of gelatin and soft, closed capsules of gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules can contain the active ingredient in the form of granules, for example mixed with fillers, such as maize starch, binders and/or lubricants, such as talc or magnesium stearate, and if appropriate stabilizers. In soft capsules, the active ingredient is preferably dissolved or

suspended in suitable liquid excipients, such as greasy oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene glycol or propylene glycol, it likewise being possible to add stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type.

Other oral forms of administration are, for example, syrups prepared in the customary manner, which comprise the active ingredient, for example, in suspended form and in a concentration of about 5 % to 20 %, preferably about 10 %, or in a similar concentration which results in a suitable individual dose, for example, when 5 or 10 ml are measured out. Other forms are, for example, also pulverulent or liquid concentrates for preparing of shakes, for example in milk. Such concentrates can also be packed in unit dose quantities.

Pharmaceutical compositions which can be used rectally are, for example, suppositories which comprise a combination of the active ingredient with a suppository base. Suitable suppository bases are, for example, naturally occurring or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.

Compositions which are suitable for parenteral administration are, in particular, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions, which comprise viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and if appropriate stabilizers. The active ingredient can also be present here in the form of a lyophilizate, if appropriate together with excipients, and be dissolved before parenteral administration by addition of suitable solvents.

Solutions such as are used, for example, for parenteral administration can also be used as infusion solutions.

Preferred preservatives are, for example, antioxidants, such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.

Ointments are oil-in-water emulsions which comprise not more than 70 %, but preferably 20 - 50 %, of water or aqueous phase. The fatty phase is, in particular, hydrocarbons, for example vaseline, paraffin oil or hard paraffins, which preferably comprise suitable hydroxy

compounds, such as fatty alcohols or esters thereof, for example cetyl alcohol or wool wax alcohols, such as wool wax, to improve the water-binding capacity. Emulsifiers are corresponding lipophilic substances, such as sorbitan fatty acid esters (Spans), for example sorbitan oleate and/or sorbitan isostearate. Additives to the aqueous phase are, for example, humectants, such as polyalcohols, for example glycerol, propylene glycol, sorbitol and/or polyethylene glycol, or such as preservatives and odoriferous substances.

Fatty ointments are anhydrous and comprise, as the base, in particular, hydrocarbons, for example paraffin, vaseline or paraffin oil, and furthermore naturally occurring or semi-synthetic fats, for example coconut-fatty acid triglycerides, or, preferably, hydrogenated oils, for example hydrogenated groundnut or castor oil, and furthermore fatty acid partial esters of glycerol, for example glycerol mono- and/or distearate, and, for example, the fatty alcohols, emulsifiers and/or additives mentioned in connection with the ointments which increase uptake of water.

Creams are oil-in-water emulsions which comprise more than 50 % of water. Oily bases used are, in particular, fatty alcohols, for example lauryl, cetyl or stearyl alcohol, fatty acids, for example palmitic or stearic acid, liquid to solid waxes, for example isopropyl myristate, wool wax or beeswax, and/or hydrocarbons, for example vaseline (petrolatum) or paraffin oil. Emulsifiers are surface-active substances with predominantly hydrophilic properties, such as corresponding nonionic emulsifiers, for example fatty acid esters of polyalcohols or ethyleneoxy adducts thereof, such as polyglyceric acid fatty acid esters or polyethylene sorbitan fatty acid esters (Tweens), and furthermore polyoxyethylene fatty alcohol ethers or polyoxyethylene fatty acid esters, or corresponding ionic emulsifiers, such as alkali metal salts of fatty alcohol sulfates, for example sodium lauryl sulfate, sodium cetyl sulfate or sodium stearyl sulfate, which are usually used in the presence of fatty alcohols, for example cetyl alcohol or stearyl alcohol. Additions to the aqueous phase are, inter alia, agents which prevent the creams from drying out, for example polyalcohols, such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, and furthermore preservatives and odoriferous substances.

Pastes are creams and ointments having secretion-absorbing powder constituents, such as metal oxides, for example titanium oxide or zinc oxide, and furthermore talc and/or aluminium silicates, which have the task of binding the moisture or secretions present.

Foams are administered from pressurized containers and are liquid oil-in-water emulsions present in aerosol form, halogenated hydrocarbons, such as chlorofluoro-lower alkanes, for example dichlorodifluoromethane and dichlorotetrafluoroethane, or, preferably, non-halogenated gaseous hydrocarbons, air, N₂O or carbon dioxide being used as the propellant gases. The oily phases used are, inter alia, those mentioned above for ointments and creams, and the additives mentioned there are likewise used.

Tinctures and solutions usually comprise an aqueous-ethanolic base to which, inter alia, polyalcohols, for example glycerol, glycols and/or polyethylene glycol, as humectants for reducing evaporation, and re-oiling substances, such as fatty acid esters with lower polyethylene glycols, i.e. lipophilic substances which are soluble in the aqueous mixture as a substitute for the fatty substances removed from the skin with the ethanol, and, if necessary, other excipients and additives, are admixed.

The invention also relates to a process or method for treatment of the disease states mentioned above, in particular those which respond to inhibition of p34^{cdc2}/cyclin B^{cdc13} kinase. The compounds of the formula I can be administered prophylactically or therapeutically as such or in the form of pharmaceutical compositions, preferably in an amount which is effective against the diseases mentioned, to a warm-blooded animal, for example a human, requiring such treatment, the compounds being used, in particular, in the form of pharmaceutical compositions. A daily dose of about 0.1 to about 5 g, preferably about 0.5 g to about 2 g, of a compound of the present invention is administered here for a body weight of about 70 kg.

The following Examples serve to illustrate the invention without limiting the scope thereof.

The short names and abbreviations used have the following meanings:

Abbreviations:

abs. absolute (anhydrous)

APCI-MS: "atmospheric pressure chemical ionization" mass spectrum

TLC-R_f R_f value according to thin layer chromatography

DMF dimethylformamide

DMPU	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
DMSO	dimethyl sulfoxide
EI-MS	electron impact ionization mass spectroscopy
sat.	saturated
h	hour(s)
HPLC	high pressure liquid chromatography
HV	high vacuum
min	minute(s)
FAB-MS	"Fast Atom Bombardment" mass spectroscopy
MS	mass spectroscopy
RT	room temperature
RE	rotary evaporator
m.p.	melting point
brine	saturated sodium chloride solution
TFA	trifluoroacetic acid
THF	tetrahydrofuran

Abbreviations for the NMR spectra data

b	broad
d	doublet
J	coupling constant
m	multiplet
q	quartet
s	singlet
t	triplet

Mobile phases (gradients):

HPLC gradients:

Grad_{20/1} 20 % → 100 % a) in b) over a period of 11 minutes, then 5 minutes in 100 % b).

Grad_{20/2} 20 % → 100 % a) in b) over a period of 20 minutes, then 8 minutes in 100 % b).

Mobile phase a): acetonitrile + 0.1 % TFA; mobile phase b): Water. Column (250 x 4.6 mm) filled with "reversed phase" material C₁₈-Nucleosil® (5 µm average particle size, silica gel derivatized covalently with octadecylsilanes, Macherey & Nagel, Düren, Germany). Detection by UV absorption at 254 nm. The retention times (t_{ret}) are stated in minutes. Flow rate 1 ml/minute.

Example 1: 250 mg (0.81 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine are dissolved in 5.8 ml (97 mmol) of ethylenediamine and the solution is heated under reflux for 3 hours (oil bath temperature of 150 °C). After cooling to room temperature, the reaction mixture is taken up in ethyl acetate (250 ml) and extracted with water (150 ml). The aqueous phase is extracted twice with ethyl acetate and the combined organic extracts are washed successively with saturated sodium hydrogen sulfate solution, water and saturated sodium chloride solution and dried over magnesium sulfate. After filtration, the filtrate is concentrated under reduced pressure at 35 °C and the residue is dried under an HV. The crude product is recrystallized from diethyl ether. 2-(2-Amino-ethyl-amino)-6-(3-chloro-phenylamino)-9-ethyl-9*H*-purine is obtained; R_f = 0.22 (methylene chloride:methanol:concentrated aqueous ammonium hydroxide solution = 900:100:1); FAB-MS: $(M+H)^+$ = 322; m.p. 79-80 °C.

The starting material is obtained as follows:

Stage 1.1: 1.4 ml (13 mmol) of 3-chloro-aniline are added to a suspension of 650 mg (3.44 mmol) of 2,6-dichloro-purine in 5 ml of 1-pentanol. The reaction mixture is stirred at 100 °C (oil bath temperature) for 3 hours. After cooling to room temperature, the mixture is diluted with isopropanol and stirred at 10 °C for 90 minutes. The precipitate is filtered off and rinsed with isopropanol and diethyl ether. The crystals are partitioned between 50 ml of 2 N (two normal) sodium hydroxide solution, 100 ml of water and 700 ml of ethyl acetate. The aqueous phase is subsequently extracted twice with ethyl acetate. The combined organic extracts are washed twice with water and once with saturated sodium chloride solution and dried over sodium sulfate. After filtration, the filtrate is concentrated under reduced pressure. The crude product is stirred with diethyl ether and the crystals are dried at 50 °C under an HV. 2-Chloro-6-(3-chloro-phenyl-amino)-purine is obtained; R_f = 0.47 (ethyl acetate:hexane = 3:1); APCI-MS: $(M+H)^+$ = 280; HPLC: t_{rel} (grad 20/1) = 10.26 minutes.

Stage 1.2: 676 mg (2.413 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-purine are dissolved in 10 ml of abs. DMF by means of gentle heating. 375 mg (2.713 mmol) of potassium carbonate, followed by 0.97 ml (12.01 mmol) of ethyl iodide are added at room temperature. The reaction mixture is stirred at room temperature for 2 hours. When the reaction is complete, the reaction mixture is poured onto ice/water (60 ml) and stirred for 10 minutes.

The inhomogeneous mixture is extracted three times with ethyl acetate. The combined organic extracts are washed twice with water and once with saturated sodium chloride solution and dried over magnesium sulfate. After filtration, the filtrate is concentrated under reduced pressure at 35 °C and dried under an HV. The resulting crude product (crystalline oil) is purified by crystallization from diethyl ether/hexane. 2-Chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained; R_f = 0.55 (ethyl acetate:hexane = 3:1); APCI-MS: $(M+H)^+$ = 308; HPLC: t_{ref} (grad 20/1) = 12.40 minutes; m.p. 127-128°C.

Example 2: Analogously to Example 1, 6-(3-chloro-phenylamino)-2-(di-[2-hydroxy-ethyl]-amino)-9-ethyl-9*H*-purine is obtained from 250 mg (0.81 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Stage 1.1] and 10 g (95 mmol) of diethanolamine; R_f = 0.29 (methylene chloride:methanol:concentrated aqueous ammonium hydroxide solution = 900:100:1); FAB-MS: $(M+H)^+$ = 377; m.p. 148-149 °C.

Example 3: Analogously to Example 1, 2-(*cis*-2-amino-cyclohexyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 250 mg (0.81 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Stage 1.1] and 5 ml (43 mmol) of (d,l)-*cis*-1,2-diamino-cyclohexane; R_f = 0.31 (methylene chloride:methanol:concentrated aqueous ammonium hydroxide solution = 900:100:1); FAB-MS: $(M+H)^+$ = 386; m.p. 111-112 °C.

Example 4: 200 mg (0.58 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-isopropyl-9*H*-purine are dissolved in 6 ml (90 mmol) of ethylenediamine and the mixture is heated under reflux for 3 hours (oil bath temperature of 150 °C). After cooling to room temperature, the reaction mixture is taken up in 250 ml of ethyl acetate and extracted with 150 ml of water. The aqueous phase is extracted twice with ethyl acetate and the combined organic extracts are washed with saturated sodium hydrogen sulfate solution, water and saturated sodium chloride solution and dried over magnesium sulfate. After filtration, the filtrate is concentrated under reduced pressure at 35 °C and dried under an HV. 2-(2-Amino-ethyl-amino)-6-(3-chloro-phenyl-amino)-9-isopropyl-9*H*-purine is obtained as a colourless foam; R_f = 0.27 (methylene chloride:methanol:concentrated ammonium hydroxide solution = 900:100:1); EI-MS: $(M+H)^+$ = 346; m.p. 55-56 °C.

The starting material is obtained as follows:

Stage 4.1: 500 mg (1.78 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-purine are dissolved in a mixture of 29.5 ml of DMF/water (85/15) and 5 ml of dioxane by means of gentle heating. 870 mg (2.67 mmol) of caesium chloride, followed by 1.78 ml (17.8 mmol) of isopropyl iodide are added at room temperature. The reaction mixture is stirred at room temperature for 18 hours. To bring the reaction to completion, the reaction mixture is stirred at 45 °C for a further 24 hours. When the reaction has ended, the reaction mixture is diluted with ethyl acetate, washed with water (2 times) and saturated sodium chloride solution and dried over magnesium sulfate. After filtration, the filtrate is concentrated under reduced pressure at 35 °C and the residue is dried under an HV. The resulting crude product is purified by crystallization from diethyl ether/hexane. 2-Chloro-6-(3-chloro-phenyl-amino)-9-isopropyl-9*H*-purine is obtained; R_f = 0.46 (ethyl acetate); m.p. 128-129°C.

Example 5: Analogously to Example 1, 6-(3-chloro-phenyl-amino)-9-ethyl-2-[(R)-2-hydroxymethylpyrrolidin-1-yl]-9*H*-purine is obtained from 250 mg (0.81 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Stage 1.2] and 5 ml (51 mmol) of D-prolinol [i.e. R(-)-prolinol]. The product is purified by digestion with diisopropyl ether; R_f = 0.52 (methylene chloride:methanol = 9:1); m.p. 164-165 °C.

Example 6: Analogously to Example 1, 2-(3-amino-propyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 308 mg (1 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Example 1, Stage 1.2] and 10.04 ml (120 mmol) of 1,3-diamino-propane. The product is purified by digestion with diisopropyl ether; R_f = 0.52 (methylene chloride:methanol:concentrated aqueous ammonium hydroxide solution = 900:100:1); FAB-MS: $(M+H)^+$ = 346; HPLC: t_{ret} (grad 20/2) = 8.07 minutes.

Example 7: Analogously to Example 1, 2-(trans-2-amino-cyclohexyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 308 mg (1 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Stage 1.2] and 6.0 ml (50 mmol) of (+/-)-trans-1,2-diamino-cyclohexane. The product is purified by digestion with diisopropyl ether; R_f = 0.19 (ethyl acetate:methanol:concentrated aqueous ammonium hydroxide solution = 900:100:1); m.p. 99.4-100.5 °C.

Example 8: Analogously to Example 1, 2-(2-hydroxy-ethyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 35 mg (0.01 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-

9-ethyl-9*H*-purine and 1.0 ml of ethanolamine after 8 hours at 150 °C; m.p. 99-102 °C; R_f = 0.3 (methylene chloride:methanol = 9:1).

Example 9: Analogously to Example 1, 2-(2-hydroxy-ethyl-amino)-6-(4-chloro-phenyl-amino)-7-ethyl-7*H*-purine is obtained from 172 mg (0.5 mmol) of 2-chloro-6-(4-chloro-phenyl-amino)-7-ethyl-7*H*-purine [also additionally contains 2-chloro-6-(4-chloro-phenyl-amino)-9-ethyl-9*H*-purine] and 1.0 ml of ethanolamine after 12 hours at 110 °C; m.p. 99-102°; R_f = 0.2 (hexane:ethyl acetate = 1:1).

The starting material is obtained as follows:

Stage 9.1: 1.0 g (5.29 mmol) of 2,6-dichloro-purine is dissolved in DMF (20 ml) and treated with 152 mg (80%, 5.3 mmol) of sodium hydride and the mixture is stirred at RT for 0.5 hours. After addition of 0.42 ml (5.3 mmol) of ethyl iodide, the mixture is stirred at 70 °C for 3 hours, diluted with ethyl acetate (100 ml) and extracted with concentrated brine. The organic phase is dried (sodium sulfate) and concentrated and the residue is chromatographed (silica gel, methylene chloride:methanol = 19:1). An oily mixture comprising 2,6-dichloro-7-ethyl-7*H*-purine and 2,6-dichloro-9-ethyl-9*H*-purine is obtained.

Stage 9.2: 465 mg (2.1 mmol) of the mixture of 2,6-dichloro-7-ethyl-7*H*-purine and 2,6-dichloro-9-ethyl-9*H*-purine are stirred in butanol (5 ml) with 1.05 g (13 mmol) of 4-chloro-aniline at 100 °C for 8 hours. After crystallization from methylene chloride and diethyl ether, 2-chloro-6-(4-chloro-phenyl-amino)-7-ethyl-7*H*-purine and 2-chloro-6-(4-chloro-phenyl-amino)-9-ethyl-9*H*-purine are obtained as white crystals.

Example 10: Analogously to Example 1, 2-benzylamino-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 154 mg (0.5 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.09 ml of benzylamine after 3.5 hours at 140 °C; m.p. 88-90 °C, FAB-MS: $(M+H)^+$ = 379.

Example 11: Analogously to Example 1, 2-(2-phenyl-ethyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 189 mg (0.613 mmol) 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.2 ml 2-phenyl-ethylamine after 16 hours at 130 °C; m.p. 151-152 °C; FAB-MS: $(M+H)^+$ = 393.

Example 12: Analogously to Example 1, 2-(3-methoxy-propyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 182 mg (0.591 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.2 ml of 3-methoxy-propylamine after 3 hours at 120 °C; m.p. 93-94 °C, FAB-MS: (M+H)⁺ = 361.

Example 13: Analogously to Example 1, 6-(3-chloro-phenyl-amino)-9-ethyl-2-(2-furyl-amino)-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.2 ml of 2-furylamine (freshly distilled) after 5.5 hours at 125 °C; m.p. 82-84 °C; FAB-MS: (M+H)⁺ = 369.

Example 14: Analogously to Example 1, 2-(2-piperidino-ethyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.2 ml 2-piperidino-ethylamine after 2 hours at 125 °C; FAB-MS: (M+H)⁺ = 400; R_f = 0.32 (methylene chloride:methanol = 9:1).

Example 15: Analogously to Example 1, 2-(tetrahydrofuryl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 g of tetrahydrofurylamine after 12 hours at 100 °C; m.p. 84-86 °C, FAB-MS: (M+H)⁺ = 373.

Example 16: Analogously to Example 1, 2-[2-(2-pyridyl)-ethyl-amino]-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.2 ml of 2-(2-amino-ethyl)-pyridine after 1.5 hours at 125 °C; m.p. 152-153 °C, FAB-MS: (M+H)⁺ = 394.

Example 17: Analogously to Example 1, 6-(3-chloro-phenyl-amino)-2-[2-(4-morpholiny)-ethyl-amino]-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 ml of 4-(2-amino-ethyl)-morpholine after 14 hours at 100 °C; FAB-MS: (M+H)⁺ = 402; R_f = 0.63 (methylene chloride:methanol = 9:1).

Example 18: Analogously to Example 1, 2-[4-(2-amino-ethyl)-piperidin-1-yl]-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 g of 4-(2-amino-ethyl)-piperidine after 1.5 hours at 100 °C; m.p. 182-184 °C; FAB-MS: (M+H)⁺ = 400.

Example 19: Analogously to Example 1, 2-[4-(2-amino-ethyl)-piperazin-1-yl]-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0,65 mmol) 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 g of 1-(2-amino-ethyl)-piperazine after 20 hours at 40 °C; FAB-MS: $(M+H)^+ = 401$; $R_f = 0.48$ (methylene chloride:methanol:concentrated aqueous ammonia solution = 90:10:1).

Example 20: Analogously to Example 1, 2-[2-(3-indolyl)-ethyl-amino]-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 g of tryptamine after 1.5 hours at 130 °C; m.p. 106-108 °C; FAB-MS: $(M+H)^+ = 432$.

Example 21: Analogously to Example 1, 2-(2-thio-ethyl-amino)-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.65 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine and 600 mg of cystamine in 3.0 ml of n-amyl alcohol after 20 hours at 140 °C; m.p. 124-127 °C, FAB-MS: $(M+H)^+ = 349$.

Example 22: Analogously to Example 1, 6-(3-chloro-phenyl-amino)-2-([1-hydroxy-cyclohex-1-yl]-methylamino)-9-ethyl-9*H*-purine is obtained from 200 mg (0.2 mmol) of 2-chloro-9-ethyl-9*H*-purine and 1000 mg of 1-(aminomethyl)-cyclohexan-1-ol after 14 hours at 120 °C; m.p. 143-145 °C, FAB-MS: $(M+H)^+ = 401$.

Example 23: Analogously to Example 1, 6-(3-chloro-phenylamino)-9-ethyl-2-piperazino-9*H*-purine is obtained from 308 mg (1 mmol) of 2-chloro-6-(3-chloro-phenyl-amino)-9-ethyl-9*H*-purine [described in Stage 1.2] and 258 mg (3 mmol) of piperazine in 10 ml of xylene. The product is purified by digestion with diisopropyl ether and hexane; $R_f = 0.44$ (ethyl acetate:methanol:concentrated ammonium hydroxide solution = 900:100:1); FAB-MS: $(M+H)^+ = 358$; m.p. 181.5-182.5 C [sic].

Example 24: 200 mg (0.58 mmol) of 2-chloro-9-ethyl-6-(3-trifluoromethyl-phenyl-amino)-9*H*-purine and 2 ml of 3-amino-1-propanol are stirred at 140 C [sic] for 2 h and the mixture is allowed to cool and is diluted with 60 ml of ethyl acetate. The organic phase is washed with water and dried over sodium sulfate. After removal of the solvent, the residue is recrystallized from ethyl acetate and diethyl ether. 9-Ethyl-2-(3-hydroxy-propyl-amino)-6-

(3-trifluoromethyl-phenyl-amino)-9*H*-purine is obtained; m.p. 136-137 C [sic]; FAB-MS: $(M+H)^+ = 381$; $R_f = 0.7$ (ethyl acetate:methanol = 9:1).

The starting material is obtained as follows:

Stage 24.1: 1.9 g (10 mmol) of 2,6-dichloro-purine and 8.05 g (50 mmol) of 3-trifluoromethyl-aniline (Fluka, Buchs, Switzerland) in 60 ml of n-butanol and 3 ml of DMF are stirred at 60 C [sic] for 6 h. 50 ml of ethyl acetate are added to the cooled reaction solution and the precipitate is filtered off and further stirred in 40 ml of isopropanol at 40 C [sic] for 60 min. After filtration with suction and drying, 2-chloro-6-(3-trifluoromethyl-phenyl-amino)-purine is obtained; m.p. 248-250 C [sic]; FAB-MS: $(M+H)^+ = 314$; $R_f = 0.45$ (CH_2Cl_2 :methanol = 95:5).

Stage 24.2: A mixture comprising 1g (3.2 mmol) of 2-chloro-6-(3-trifluoromethyl-phenyl-amino)-purine, 1.7 g (5.1 mmol) of caesium carbonate and 2.1 ml (25.6 mmol) of ethyl iodide in 7 ml of dioxane/water/DMF (8:2:2) is stirred at RT for 18 h. It is then diluted with ethyl acetate and the organic phase is washed with water. This phase is separated off and dried over Na_2SO_4 . After removal of the solvent, the residue is recrystallized from ethyl acetate and diethyl ether. 2-Chloro-9-ethyl-6-(3-trifluoromethyl-phenyl-amino)-9*H*-purine is obtained; m.p. 129-130 C [sic]; FAB-MS: $(M+H)^+ = 342$; $R_f = 0.6$ (CH_2Cl_2 :methanol = 9:1).

Example 25: Analogously to Example 24, 9-ethyl-2-(3-hydroxy-propyl-amino)-6-[3-(3-hydroxy-propyl)-aminocarbonyl]-2-methyl-phenyl-amino]-9*H*-purine is obtained from 140 mg (0.4 mmol) of 2-chloro-6-(3-ethoxycarbonyl-2-methyl-phenyl-amino)-9-ethyl-9*H*-purine and 1.5 ml of 3-amino-1-propanol after 4 h at 110 C [sic]; m.p. 138-142 C [sic]; FAB-MS: $(M+H)^+ = 428$; $R_f = 0.7$ (CH_2Cl_2 :methanol = 7:3).

The starting material is obtained as follows:

Stage 25.1: Analogously to Stage 104.1, 2-chloro-6-(3-ethoxycarbonyl-2-methyl-phenyl-amino)-purine is obtained from 1.2 g (6.4 mmol) of 2,6-dichloro-purine and 1.5 g (9.1 mmol) of ethyl 3-amino-2-methyl-benzoate (prepared by the method of Fringuelli et.al., Tetrahedron 1969, 25, 4249) in 25 ml of n-butanol after stirring at 75 C [sic] for 48 h; m.p. 235-236 C [sic]; FAB-MS: 318 $(M+H)^+$; $R_f = 0.5$ (CH_2Cl_2 : methanol = 9:1).

Stage 25.2: Analogously to Stage 24.2, 2-chloro-6-(3-ethoxycarbonyl-2-methyl-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 500 mg (1.57 mmol) of 2-chloro-6-(3-ethoxycarbonyl-2-methyl-phenyl-amino)-purine, 1.01 g (3.15 mmol) of caesium carbonate and 1.3 ml (15 mmol) of ethyl iodide in 20 ml of DMF/water (9:1) after 6 h at RT; m.p. 142-144 C [sic]; FAB-MS: (M+H)⁺ = 346; R_f = 0.5 (ethyl acetate:acetone = 12:1).

Example 26: Analogously to Stage 24.2, 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-9-ethyl-9*H*-purine is obtained from 100 mg (0.32 mmol) of 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-purine, 208 mg (0.64 mmol) of caesium carbonate and 250 mg (1.6 mmol) of ethyl iodide in 4 ml of DMF/water (9:1) after 48 h at RT; m.p. 130-131 C [sic]; FAB-MS: (M+H)⁺ = 343; R_f = 0.55 (CH₂Cl₂:methanol = 9:1).

The starting material is obtained as follows:

Stage 26.1: Analogously to Stage 24.1, 2-chloro-6-(3-methoxy-phenyl-amino)-purine is obtained from 1.9 g (10 mmol) of 2,6-dichloro-purine and 1.5 g (12 mmol) of m-anisidine (Fluka, Buchs, Switzerland) in n-butanol/DMF (18:3) after stirring at 50 C [sic] for 4 h; m.p. 245-246 C [sic]; FAB-MS: (M+H)⁺ = 276; R_f = 0.75 (CH₂Cl₂:methanol = 8:2).

Stage 26.2: Analogously to Example 24, 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-purine is obtained from 0.96 g (3.5 mmol) of 2-chloro-6-(3-methoxy-phenyl-amino)-purine and 8 ml of 3-amino-1-propanol after stirring at 150 C [sic] for 5 h; m.p. 199-200 C [sic]; FAB-MS: (M+H)⁺ = 315; R_f = 0.15 (CH₂Cl₂:methanol = 9:1).

Example 27: Analogously to Stage 24.2, 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-9-isopropyl-9*H*-purine is obtained from 180 mg (0.57 mmol) of 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-purine (cf. Stage 26.2), 372 mg (1.14 mmol) of caesium carbonate and 0.3 ml (0.003 mmol) of isopropyl iodide in 5 ml of DMF/water (9:1) after 16 h at 60 C [sic]; m.p. 128-129 C [sic]; FAB-MS: (M+H)⁺ = 357; R_f = 0.5 (CH₂Cl₂:methanol = 9:1).

Example 28: Analogously to Stage 24.2, 9-(2-hydroxy-ethyl)-2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-9*H*-purine is obtained from 180 mg (0.57 mmol) of 2-(3-hydroxy-propyl-amino)-6-(3-methoxy-phenyl-amino)-purine (cf. Stage 26.2), 372 mg (1.14 mmol) of

caesium carbonate and 0.33 ml (3 mmol) of 2-iodo-ethanol in 5 ml of DMF/water (9:1) after 18 h at 60 C [sic]; m.p. 132-133 C [sic]; FAB-MS: $(M+H)^+ = 359$; $R_f = 0.5$ (CH_2Cl_2 :methanol = 9:1).

Example 29: Analogously to Example 24, 9-ethyl-2-[2-(4-imidazolyl)-ethyl-amino]-6-(3-methoxy-phenyl-amino)-9*H*-purine is obtained from 91 mg (0.3 mmol) of 2-chloro-9-ethyl-6-(3-methoxy-phenyl-amino)-9*H*-purine and 1.1 g (10 mmol) of 2-(4-imidazolyl)-ethylamine (Fluka, Buchs, Switzerland) after 2 h at 120 C [sic]; FAB-MS: $(M+H)^+ = 379$; $R_f = 0.15$ (CH_2Cl_2 :methanol = 9:1).

The starting material is obtained as follows:

Stage 29.1: Analogously to Stage 24.2, 2-chloro-9-ethyl-6-(3-methoxy-phenyl-amino)-9*H*-purine is obtained from 1.5 g (5.44 mmol) of 2-chloro-6-(3-methoxy-phenyl-amino)-purine (cf. Stage 26.1), 8.5 g (54.4 mmol) of ethyl iodide and 2.6 g (8.1 mmol) of caesium carbonate in 45 ml of dioxane/water/DMF (8:15:85) after 6 h at RT; m.p. 158-159 C [sic]; FAB-MS: $(M+H)^+ = 303$; $R_f = 0.65$ (CH_2Cl_2 :methanol = 9:1).

Example 30: Analogously to Example 24, 2-(3-hydroxy-propyl-amino)-6-(3,4,5-trimethoxy-phenyl-amino)-9-methyl-9*H*-purine is obtained from 70 mg (0.2 mmol) of 2-chloro-9-methyl-6-(3,4,5-trimethoxy-phenyl-amino)-9*H*-purine and 0.23 ml (1.5 mmol) of 3-amino-1-propanol after 2 h at 150 C [sic]; m.p. 166-167 C [sic]; FAB-MS: $(M+H)^+ = 389$; $R_f = 0.35$ (CH_2Cl_2 :methanol = 9:1).

The starting material is obtained as follows:

Stage 30.1: Analogously to Stage 24.1, 2-chloro-6-(3,4,5-trimethoxy-phenyl-amino)-purine is obtained from 1.5 g (7.9 mmol) of 2,6-dichloro-purine and 1.45 g (7.9 mmol) of 3,4,5-trimethoxy-aniline (Fluka, Buchs, Switzerland); m.p. 265 C [sic]; FAB-MS: $(M+H)^+ = 336$; $R_f = 0.3$ (CH_2Cl_2 :methanol = 9:1).

Stage 30.2: 168 mg (0.5 mmol) of 2-chloro-6-(3,4,5-trimethoxy-phenyl-amino)-purine, 103 mg (0.75 mmol) of potassium carbonate and 0.156 ml (2.5 mmol) of methyl iodide are stirred in 3 ml of dimethylformamide at room temperature for 5 h. 30 ml of ethyl acetate are

added to the slightly cloudy reaction solution and the mixture is extracted with water. The organic phase is dried over sodium sulfate. After removal of the solvent, the residue is recrystallized from ethyl acetate and diethyl ether. 2-Chloro-6-(3,4,5-trimethoxy-phenyl-amino)-9-methyl-9*H*-purine is obtained; FAB-MS: (M+H)⁺ = 350; R_f = 0.6 (CH₂Cl₂:methanol = 9:1).

Example 31: The following compounds of the formula I are obtained analogously to the processes described in this text:

- a) 2-[(3-aminomethyl-phenyl)-methyl-amino]-6-(3-chloro-phenylamino)-9-ethyl-9*H*-purine,
- b) 2-(2-methylamino-ethyl-amino)-6-(3-chloro-phenylamino)-9-ethyl-9*H*-purine and
- c) 2-[2-(2-amino-ethyl-amino)-ethyl-amino]-6-(3-chloro-phenylamino)-9-ethyl-9*H*-purine.

Example 32: Dry capsules

5000 capsules, each of which contain 0.25 g of one of the compounds of the formula I mentioned in the preceding Examples as active ingredient, are prepared as follows:

Composition

Active ingredient	1250 g
Talc	180 g
Wheat starch	120 g
Magnesium stearate	80 g
Lactose	20 g

Preparation process: The powdered substances mentioned are pressed through a sieve of mesh width 0.6 mm. Portions of 0.33 g of the mixture are transferred to gelatin capsules with the aid of a capsule-filling machine.

Example 33: Soft capsules

5000 soft gelatin capsules, each of which contain 0.05 g of one of the compounds of the formula I mentioned in the preceding Examples as active ingredient are prepared as follows:

Composition

Active ingredient	250 g
-------------------	-------

Lauroglycol 2 litres

Preparation process: The powdered active ingredient is suspended in Lauroglykol® (propylene glycol laurate, Gattefossé S.A., Saint Priest, France) and ground in a wet-pulverizer to a particle size of about 1 to 3 µm. Portions of in each case 0.419 g of the mixture are then transferred to soft gelatin capsules by means of a capsule-filling machine.

Example 34: Soft capsules

5000 soft gelatin capsules, each of which contain 0.05 g of one of the compounds of the formula I mentioned in the preceding Examples as active ingredient, are prepared as follows:

Composition

Active ingredient	250 g
PEG 400	1 litre
Tween 80	1 litre

Preparation process: The powdered active ingredient is suspended in PEG 400 (polyethylene glycol of M_r between about 380 and about 420, Fluka, Switzerland) and Tween® 80 (polyoxyethylene sorbitan monolaurate, Atlas Chem. Ind., Inc., USA, supplied by Fluka, Switzerland) and ground in a wet-pulverizer to a particle size of about 1 to 3 µm. Portions of in each case 0.43 g of the mixture are then transferred to soft gelatin capsules by means of a capsule-filling machine.